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1. INTRODUCTION 
Nanoparticles are defined as particulate dispersions or solid particles with a size in the 
range of 10-1000nm. The drug is dissolved, entrapped, encapsulated or attached to a nanoparticle 
matrix. Depending upon the method of preparation, nanoparticles, nanospheres or nanocapsules 
can be obtained. Nanocapsules are systems in which the drug is confined to a cavity surrounded 
by a unique polymer membrane, while nanospheres are matrix systems in which the drug is 
physically and uniformly dispersed. In recent years, biodegradable polymeric nanoparticles, 
particularly those coated with hydrophilic polymer such as poly(ethylene glycol) (PEG) known 
as long-circulating particles, have been used as potential drug delivery devices because of their 
ability to circulate for a prolonged period time target a particular organ, as carriers of DNA in 
gene therapy, and their ability to deliver proteins, peptides and genes 1.  
The major goals in designing nanoparticles as a delivery system are to control particle 
size, surface properties and release of pharmacologically active agents in order to achieve the 
site-specific action of the drug at the therapeutically optimal rate and dose regimen. Though 
liposomes have been used as potential carriers with unique advantages including protecting drugs 
from degradation, targeting to site of action and reduction toxicity or side effects, their 
applications are limited due to inherent problems such as low encapsulation efficiency, rapid 
leakage of water-soluble drug in the presence of blood components and poor storage stability. On 
the other hand, polymeric nanoparticles offer some specific advantages over liposomes. For 
instance, they help to increase the stability of drugs/proteins and possess useful controlled release 
properties 2.  
ADVANTAGES OF NANOPARTICLES 3 
 Suitable for different routes of administration. 
 Carrying capacity of nanoparticles is high. 
 Shelf stability of drug increase. 
 Ability of sustain and control drug release pattern. 
 System increases the bioavailability drugs. 
 Used for targeted drug delivery of drugs. 
 Development of new medicine which are safer.   
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1.1. TARGETED DRUG DELIVERY SYSTEM1 
 
 Targeted delivery can be achieved by either active or passive targeting. Active targeting 
of a therapeutic agent is achieved by conjugating the therapeutic agent or the carrier system to a 
tissue or cell-specific ligand. Passive targeting is achieved by incorporating the therapeutic agent 
into a macromolecule or nanoparticle that passively reaches the target organ. Target drug 
delivery system has been developed to optimize regenerative technique. The system is based on 
method that delivers a certain amount of a therapeutic agent for prolonged period of time to a 
target diseased area within the body. This helps maintain in the required plasma and tissue drug 
level in body. Therefore avoid any damage to the healthy tissue via drug. 
 
An ideal carrier engineered as targetable device should have following features; 
 Must be able to cross anatomical barrier. 
 Must be recognized specifically and selectively by the target cells. 
 Linkage of the drug and directing unit (ligand) should be stable in plasma. 
 Should be non toxic, nonimmunogenic and biodegradable after recognition and release 
     drug moiety. 
1.2. NANOPARTICLES DRUG DELIVERY SYSTEM4 
 
Nanoparticles are solid, colloidal particles consisting of macromolecular substances that 
vary in size from 10 nm to 1000 nm. The drug of interest is dissolved, entrapped, adsorbed, 
attached or encapsulated into the nanoparticle matrix. Depending on the method of preparation, 
nanoparticles, nanospheres or nanocapsules can be obtained with different properties and release 
characteristics for the encapsulated therapeutic agent. Nanocapsules are vesicular systems in 
which the drug is confined to a cavity surrounded by a polymer membrane, whereas nanospheres 
are matrix systems in which the drug is physically and uniformly dispersed.  
 Matrix type nanosphere, drug molecules are evenly dispersed in the polymer matrix. 
 Core shell nanocapsule, drug molecule is presented in a core covered with a polymer 
shell. 
 Matrix type nanosphere where drug crystals are embedded in a polymer matrix. 
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POLYMERIC NANOPARTICLES4 
 
These are colloidal particles ranging in the size from 10-1000 nm. They consist of 
macromolecular materials and can be used therapeutically, e.g. as adjuvant in vaccines, drug 
carriers in  which the active principle (Drug or biological active material) is dissolved entrapped 
or encapsulated and the active principle is adsorbed or attached. 
 
The concept of using nanoparticle for drug delivery was developed first by speiser and 
co-workers in the late 1960 and early 1970s when cross –linked polyacrylamide nanoparticles 
are produced by the polymerization of acrylamide and NN-Methylene bisacrylamide after 
secondary solubilisation in an organic solvent such as hexane. The active ingredients, drug or 
antigen, were incorporated into the solubilised aqueous phase because of the larger amount of 
organic solvents and surfactant used for the manufactures to develop nanoparticles, the process is 
now only of historical interest. Polymeric nanoparticles are composed of biodegradable or bio 
stable polymer and copolymer. The active agents can be; 
 
 Entrapped or encapsulate within the particles 
 physically adsorbed on surface 
 Chemically linked to the surface of the nanoparticles. 
 Nanoparticles have been explored for the delivery of anti-HIV molecules  
        
   And it used to target anti retrovirals; 
(i) Macrophage/monocytes 
(ii) CNS which act as viral reservoir sites during HIV 
 
Polymer used in Preparation of polymeric Nanoparticles 
Polymer used in manufacturing of polymeric nanoparticles is of two types:                
1. Natural hydrophilic polymers (protein and polysaccharides) 
2. Synthetic hydrophobic polymers (poly lactic acid and PLGA) 
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Natural Hydrophilic polymers; 
Albumin, gelatin, legumin or vicilin as polysaccharides like alginates or agarose have 
been extensively studied and characterized. These macromolecules are used due to their intrinisic 
biodegradability and biocompatibility. 
 
Disadvantages with natural polymers are; 
 Batch to batch variation 
 Conditional biodegradability 
 Antigenicity 
 
Synthetic Hydrophobic polymers; 
Polymers which are used for microspheres preparation are used for nanoparticles 
preparation. Most of them are hydrophobic in nature. The polymers are either pre –polymerized 
or synthesized during nanoparticles preparation. Eg; Poly (€-caprolactone) (PECL), Poly(lactic 
acid)(PLA), poly (lactic de-co glycolide)(PLGA), poly styrene etc., 
 
1.3. FORMULATION TECHNIQUE OF NANOPARTICLES  
 
The selection of the appropriate method for the preparation of nanoparticles depends on 
the physiochemical characteristics of the polymer and the drug to be loaded4, 5 
Two types of systems with different inner structures are apparently possible they are; 
1. A matrix type system containing of an entanglement of oligomer or polymer units 
(nanoparticles/nanocapsules) 
2. A reservoir type of system comprised of an oily core surrounded by an embryonic 
polymeric shell (nanocapsule) 
The drug can either be entrapped within the reservoir or matrix or be adsorbed on the 
surface of these particulate systems. The polymers are strictly structured to a nanomeric size 
range using appropriate methodologies. They are classified; 
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Amphiphilic macromolecules cross-linking 
 Heat cross-linking        
 Chemical cross-linking      
 
Polymerization based methods 
 Polymerization of monomers insitu 
 Emulsion (micellar) polymerization 
 Dispersion polymerization 
 Interfacial condensation polymerization 
 Interfacial complexation 
Polymer precipitation methods 
 Solvent extraction/evaporation 
 Solvent displacement (nanoprecipitation) 
 Salting out 
 Solvent evaporation 
 
PRECIPITATION METHOD: 
The hydrophobic polymer and hydrophobic drug is dissolved in a particular organic 
solvent followed by its dispersion in a continuous aqueous phase, in which the polymer is 
insoluble. Precipitation of the polymer produces nanoparticles with drug loaded in it. The 
external phase also contains the stabilizer. Depending upon solvent miscibility techniques they 
are designated as solvent/evaporation method. Polymer precipitation can be brought out by 
increasing the solubility of the organic solvent in the external medium by adding an alcohol. 
Organic solvent is completely soluble in the continuous phase-nanoprecipitation. 
A. Extraction method Solvent; 
The preparation of nanoparticles starts with formulation of conventional O/W emulsion 
between a partially water miscible solvent containing the polymer and the drug, and an aqueous 
phase containing the stabilizer. The subsequent removal of solvent (solvent evaporation method) 
or addition of water to the system so as to diffuse the solvent to the external phase 
(emulsification diffusion method) is the two variance of the solvent extraction method. 
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The classical procedure nanospheres is the polymer, solubilized in a solvent and 
dispensed in a gelatin solution by sonication to yield emulsion (O/W) then the solvent is 
eliminated by evaporation. The homogenizer breaks the initial coarse emulsion in nanodroplets 
(nanofludization) yielding nanospheres with a narrow –size distribution. 
 
B. Double Emulsion solvent Evaporation method; 
Emulsion solvent evaporation technique has been further modified and a double emulsion 
(or multiple emulsion) of water in oil in water type has been used. Following evaporation of the 
organic solvent(s) nanoparticles are formed which are then recovered by ultracentrifugation, 
washed repeatedly with buffer and lyophilized. 
 
Polymer are dissolved separately in aqueous and organic phases respectively containing 
stabilizer and subjected to ultra-sonication to yield water in oil emulsion (W/O) This W/O is 
further added to a PVA aqueous solution to yield the water in oil in water double emulsion 
(W/O/W) The organic solvent is allowed to evaporate while being stirred first at atmosphere 
pressure for 16 h and then gradually at reduced pressure to yield nanoparticles. 
 
 
C. Solvent Displacement or Nanoprecipitation 
It is based on interfacial deposition of a polymer following displacement of semi-polar 
solvent miscible with water from a lipophilic solution. Solvent displacement method involves the 
use of an organic phase, which is completely soluble in the external aqueous phase, inducing 
immediate miscibility of both the phases. After nanoparticles preparation, the solvent is 
eliminated and the free flowing nanoparticles can be obtained under pressure. The method is 
particularly useful for drugs that are slightly soluble in water. If the drug is highly hydrophilic, It 
is diffused out into external aqueous phase, where as if the drug is highly hydrophobic, it may 
precipitate in the aqueous as nanocrystals, which further grow during storage. In the case of 
hydrophilic polymer, an aqueous solution of polymer is dispersed or emulsified in oil phase. 
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D. Salting out 
It is one commonly, used method used for preparation of nanoparticle. This method, 
involves the mixing of saturated aqueous solution of polyvinyl alcohol (PVA) into an acetone 
solution of the polymer under magnetic stirring resulting in the formation of o/w emulsion. The 
precipitation of the polymer occurs when sufficient amount of water is added to external phase to 
allow complete diffusion of the acetone from internal phase into aqueous phase. 
 
E. Solvent evaporation 
 The solvent evaporation method is a well-established and frequently used method for the 
manufacturing of particles with sizes above 1 nm and also sizes of less than 1000 nm. In this 
process the preformed polymer and the drug are dissolved in a volatile, water-immiscible organic 
solvent. This organic phase is then added to the aqueous phase under stirring, and the organic 
solvent is removed by heating and/or under reduced pressure. The polymer precipitates and 
forms micro- or nanospheres instantaneously containing the drug dispersed in the polymer 
matrix. 
 
1.4. MECHANISM OF DRUG RELEASE  
 
The polymeric drug carriers deliver the drug at the tissue site by any one of the three 
general physico-chemical mechanisms.  
1. By the swelling of the polymer nanoparticles by hydration followed by release through 
diffusion.  
2. By an enzymatic reaction resulting in rupture or cleavage or degradation of the 
polymer at site of delivery, there by releasing the drug from the entrapped inner core.  
3. Dissociation of the drug from the polymer and its de-adsorption/release from the 
swelled nanoparticles. 
 
1.5. Characteristics of Nanoparticles   
Particle size and size distribution are the most important characteristics of nanoparticle 
systems. They determine the in vivo distribution, biological fate, toxicity and the targeting ability 
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of nanoparticle systems. In addition, they can also influence the drug loading, drug release and 
stability of nanoparticles.  
Many studies have demonstrated that nanoparticles of sub-micron size have a number of 
advantages over microparticles as a drug delivery system6. Generally nanoparticles have 
relatively higher intracellular uptake compared to microparticles and available to a wider range 
of biological targets due to their small size and relative mobility. Desai et al found that 100 nm 
nanoparticles had a 2.5 fold greater uptake than 1 µm microparticles, and 6 fold greater uptake 
than 10 µm microparticles in a Caco-2 cell line 7.  
In a subsequent study, the nanoparticles penetrated throughout the sub mucosal layers in 
a rat in situ intestinal loop model, while micro particles were predominantly localized in the 
epithelial lining. It was also reported that nanoparticles can across the blood-brain barrier 
following the opening of tight junctions by hyper osmotic mannitol, which may provide 
sustained delivery of therapeutic agents for difficult-to-treat diseases like brain tumors.  
Tween 80 coated nanoparticles have been shown to cross the blood-brain barrier. In some 
cell lines, only submicron nanoparticles can be taken up efficiently but not the larger size 
microparticles 8. 
  Drug release is affected by particle size. Smaller particles have larger surface area, 
therefore, most of the drug associated would be at or near the particle surface, leading to fast 
drug release. Whereas, larger particles have large cores which allow more drug to be 
encapsulated and slowly diffuse out. Smaller particles also have greater risk of aggregation of 
particles during storage and transportation of nanoparticle dispersion. It is always a challenge to 
formulate nanoparticles with the smallest size possible but maximum stability.  
Polymer degradation can also be affected by the particle size. For instance, the rate of 
PLGA polymer degradation was found to increase with increasing particle size in vitro 9. It was 
thought that in smaller particles, degradation products of PLGA formed can diffuse out of the 
particles easily while in large particles, degradation products are more likely remained within the 
polymer matrix for a longer period to cause autocatalytic degradation of the polymer material. 
Therefore, it was hypothesized that larger particles will contribute to faster polymer degradation 
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as well as the drug release. However, Panyam et al prepared PLGA particles with different size 
ranges and found that the polymer degradation rates in vitro were not substantially different for 
different size particles.  
Currently, the fastest and most routine method of determining particle size is by photon-
correlation spectroscopy or dynamic light scattering. Photon-correlation spectroscopy requires 
the viscosity of the medium to be known and determines the diameter of the particle by 
Brownian motion and light scattering properties. The results obtained by photon-correlation 
spectroscopy are usually verified by scanning or transmission electron microscopy (SEM or 
TEM).  
1.6. Surface properties of nanoparticles  
When nanoparticles are administered intravenously, they are easily recognized by the 
body immune systems, and are then cleared by phagocytes from the circulation 10. Apart from 
the size of nanoparticles, their surface hydrophobicity determines the amount of adsorbed blood 
components, mainly proteins (opsonins). This in turn influences the in vivo fate of nanoparticles. 
Binding of these opsonins onto the surface of nanoparticles called opsonization acts as a bridge 
between nanoparticles and phagocytes. The association of a drug to conventional carriers leads to 
modification of the drug biodistribution profile, as it is mainly delivered to the mononuclear 
phagocytes system (MPS) such as liver, spleen, lungs and bone marrow. 
  Hence, to increase the likelihood of the success in drug targeting by nanoparticles, it is 
necessary to minimize the opsonization and to prolong the circulation of nanoparticles in vivo. 
This can be achieved by (a) surface coating of nanoparticles with hydrophilic 
polymers/surfactants; (b) formulation of nanoparticles with biodegradable copolymers with 
hydrophilic segments such as polyethylene glycol (PEG), polyethylene oxide, polyoxamer, 
poloxamine and polysorbate 80 (Tween 80). 
  The zeta potential of a nanoparticle is commonly used to characterize the surface charge 
property of nanoparticles. It reflects the electrical potential of particles and is influenced by the 
composition of the particle and the medium in which it is dispersed. Nanoparticles with a zeta 
potential above (+/-) 30 mV have been shown to be stable in suspension, as the surface charge 
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prevents aggregation of the particles. The zeta potential can also be used to determine whether a 
charged active material is encapsulated within the centre of the nanocapsule or adsorbed onto the 
surface. 
1.7. Drug loading 
  Ideally, a successful nanoparticulate system should have a high drug-loading capacity 
thereby reduce the quantity of matrix materials for administration. Drug loading can be done by 
two methods: 
 • Incorporating at the time of nanoparticles production (incorporation method) 
 • Absorbing the drug after formation of nanoparticles by incubating the carrier with a 
concentrated drug solution (adsorption /absorption technique).  
Drug loading and entrapment efficiency very much depend on the solid-state drug 
solubility in matrix material or polymer (solid dissolution or dispersion), which is related to the 
polymer composition, the molecular weight, the drug polymer interaction and the presence of 
functional groups (ester or carboxyl) 11,12,13. The PEG moiety has no or little effect on drug 
loading. The macromolecule or protein shows greatest loading efficiency when it is loaded at or 
near its isoelectric point when it has minimum solubility and maximum adsorption 19 For small 
molecules, studies show the use of ionic interaction between the drug and matrix materials can 
be a very effective way to increase the drug loading14. 
1.8. Applications of Nanoparticulate Delivery Systems  
Tumor targeting using nanoparticulate delivery systems  
  Nanoparticles will be able to deliver a concentrate dose of drug in the vicinity of the 
tumor targets via the enhanced permeability and retention effect or active targeting by ligands on 
the surface of nanoparticles.  Nanoparticles will reduce the drug exposure of health tissues by 
limiting drug distribution to target organ. 
 Recently Bibby et al reported the biodistribution and pharmacokinetics (PK) of a cyclic 
RGD doxorubicin-nanoparticle formulation in tumorbearing mice. Their biodistribution studies 
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revealed decreasing drug concentrations over time in the heart, lung, kidney and plasma and 
accumulating drug concentrations in the liver, spleen and tumor. The majority injected dose 
appeared in the liver (56%) and only 1.6% in the tumour at 48 hrs post injection, confirming that 
nanoparticles have a great tendency to be captured by liver. This indicates the greatest challenge 
of using nanoparticles for tumour targeting is to avoid particle uptake by mononuclear 
phagocytic system (MPS) in liver and spleen. 
Long circulating nanoparticles  
To be successful as a drug delivery system, nanoparticles must be able to target tumors 
which are localized outside MPS-rich organs. In the past decade, a great deal of work has been 
devoted to developing so-called “stealth” particles or PEGylated nanoparticles, which are 
invisible to macrophages or phagocytes. A major breakthrough in the field came when the use of 
hydrophilic polymers (such as polyethylene glycol, poloxamines, poloxamers, and 
polysaccharides) to efficiently coat conventional nanoparticle surface produced an opposing 
effect to the uptake by the MPS. These coatings provide a dynamic “cloud” of hydrophilic and 
neutral chains at the particle surface which repel plasma proteins. As a result, those coated 
nanoparticles become invisible to MPS, therefore, remained in the circulation for a longer period 
of time. Hydrophilic polymers can be introduced at the surface in two ways, either by adsorption 
of surfactants or by use of block or branched copolymers for production of nanoparticles 15, 16. 
  Studies show nanoparticles containing a coat of PEG not only have a prolonged half-life 
in the blood compartment but also be able to selectively extravasate in pathological sites such as 
tumors or inflamed regions with a leaky vasculature. As a result, such long-circulating 
nanoparticles have increased the potential to directly target tumors located outside MPS-rich 
regions.  
Targeting with small ligands appears more likely to succeed since they are easier to 
handle and manufacture. Furthermore, it could be advantageous when the active targeting ligands 
are used in combination with the long-circulating nanoparticles to maximize the likelihood of the 
success in active targeting of nanoparticles. 
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Reversion of multidrug resistance in tumour cells  
Anticancer drugs, even if they are located in the tumour interstitium, can turn out to be of 
limited efficacy against numerous solid tumour types, because cancer cells are able to develop 
mechanisms of resistance17. These mechanisms allow tumours to evade chemotherapy. 
Multidrug resistance (MDR) is one of the most serious problems in chemotherapy. MDR occurs 
mainly due to the over expression of the plasma membrane pglycoprotein (Pgp), which is 
capable of extruding various positively charged xenobiotics, including some anticancer drugs, 
out of cells. In order to restore the tumoral cells’ sensitivity to anticancer drugs by circumventing 
Pgp-mediated MDR, several strategies including the use of colloidal carriers have been applied. 
The rationale behind the association of drugs with colloidal carriers, such as nanoparticles, 
against drug resistance derives from the fact that Pgp probably recognizes the drug to be effluxed 
out of the tumoral cells only when this drug is present in the plasma membrane, and not when it 
is located in the cytoplasm or lysosomes after endocytosis.  
Nanoparticles for oral delivery of peptides and proteins 
 Significant advances in biotechnology and biochemistry have led to the discovery of a 
large number of bioactive molecules and vaccines based on peptides and proteins. Development 
of suitable carriers remains a challenge due to the fact that bioavailability of these molecules is 
limited by the epithelial barriers of the gastrointestinal tract and their susceptibility to 
gastrointestinal degradation by digestive enzymes. Polymeric nanoparticles allow encapsulation 
of bioactive molecules and protect them against enzymatic and hydrolytic degradation. For 
instance, it has been found that insulin-loaded nanoparticles have preserved insulin activity and 
produced blood glucose reduction in diabetic rats for up to 14 days following the oral 
administration.  
The surface area of human mucosa extends to 200 times that of skin. The gastrointestinal 
tract provides a variety of physiological and morphological barriers against protein or peptide 
delivery, e.g., (a) proteolytic enzymes in the gut lumen like pepsin, trypsin and chymotrypsin; (b) 
proteolytic enzymes at the brush border membrane (endopeptidases); (c) bacterial gut flora; and 
(d) mucus layer and epithelial cell lining itself. The histological architecture of the mucosa is 
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designed to efficiently prevent uptake of particulate matter from the environment. One important 
strategy to overcome the gastrointestinal barrier is to deliver the drug in a colloidal carrier 
system, such as nanoparticles, which is capable of enhancing the interaction mechanisms of the 
drug delivery system and the epithelia cells in the GI tract 19.  
Targeting of nanoparticles to epithelial cells in the GI tract using ligands  
Targeting strategies to improve the interaction of nanoparticles with adsorptive 
enterocytes and M-cells of Peyer’s patches in the GI tract can be classified into those utilizing 
specific binding to ligands or receptors and those based on nonspecific adsorptive mechanism. 
The surface of enterocytes and M cells display cell-specific carbohydrates, which may serve as 
binding sites to colloidal drug carriers containing appropriate ligands. Certain glycoproteins and 
lectins bind selectively to this type of surface structure by specific receptor-mediated 
mechanism. Different lectins, such as bean lectin and tomato lectin, have been studied to 
enhance oral peptide adsorption. Vitamin B-12 absorption from the gut under physiological 
conditions occurs via receptor-mediated endocytosis. The ability to increase oral bioavailability 
of various peptides (e.g., granulocyte colony stimulating factor, erythropoietin) and particles by 
covalent coupling to vitamin B-12 has been studied. For this intrinsic process, mucoprotein is 
required, which is prepared by the mucus membrane in the stomach and binds specifically to 
cobalamin. The mucoprotein completely reaches the ileum where resorption is mediated by 
specific receptors 20.Absorption enhancement using non-specific interactions. 
 In general, the gastrointestinal absorption of macromolecules and particulate materials 
involves either paracellular route or endocytotic pathway. The paracellular route of absorption of 
nanoparticles utilises less than 1% of mucosal surface area. Using polymers such as chitosan, 
starch or poly (acrylate) can increase the paracellular permeability of macromolecules. 
Endocytotic pathway for absorption of nanoparticles is either by receptor-mediated endocytosis, 
that is, active targeting, or adsorptive endocytosis which does not need any ligands. This process 
is initiated by an unspecific physical adsorption of material to the cell surface by electrostatic 
forces such as hydrogen bonding or hydrophobic interactions. Adsorptive endocytosis depends 
primarily on the size and surface properties of the material. If the surface charge of the 
nanoparticles is positive or uncharged, it will provide an affinity to adsorptive enterocytes though 
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hydrophobic, whereas if it is negatively charged and hydrophilic, it shows greater affinity to 
adsorptive enterocytes and M cells. This shows that a combination of size, surface charge and 
hydrophilicity play a major role in affinity. This is demonstrated with poly (styrene) 
nanoparticles and when it is carboxylated 21. 
 Nanoparticles for gene delivery 
  Polynucleotide vaccines work by delivering genes encoding relevant antigens to host 
cells where they are expressed, producing the antigenic protein within the vicinity of professional 
antigen presenting cells to initiate immune response. Such vaccines produce both humoral and 
cell-mediated immunity because intracellular production of protein, as opposed to extracellular 
deposition, stimulates both arms of the immune system. The key ingredient of polynucleotide 
vaccines, DNA, can be produced cheaply and has much better storage and handling properties 
than the ingredients of the majority of protein-based vaccines. Hence, polynucleotide vaccines 
are set to supersede many conventional vaccines particularly for immunotherapy. However, there 
are several issues related to the delivery of poly nucleotides which limit their application. These 
issues include efficient delivery of the polynucleotide to the target cell population and its 
localization to the nucleus of these cells, and ensuring that the integrity of the polynucleotide is 
maintained during delivery to the target site.  
Nanoparticles loaded with plasmid DNA could also serve as an efficient sustained release 
gene delivery system due to their rapid escape from the degradative endo-lysosomal 
compartment to the cytoplasmic compartment. Hedley et al reported that following their 
intracellular uptake and endolysosomal escape, nanoparticles could release DNA at a sustained 
rate resulting in sustained gene expression. This gene delivery strategy could be applied to 
facilitate bone healing by using PLGA nanoparticles containing therapeutic genes such as bone 
morphogenic protein. 
 Nanoparticles for drug delivery into the brain 
 The blood-brain barrier (BBB) is the most important factor limiting the development of 
new drugs for the central nervous system. The BBB is characterized by relatively impermeable 
endothelial cells with tight junctions, enzymatic activity and active efflux transport systems. It 
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effectively prevents the passage of water-soluble molecules from the blood circulation into the 
CNS, and can also reduce the brain concentration of lipid-soluble molecules by the function of 
enzymes or efflux pumps. Consequently, the BBB only permits selective transport of molecules 
that are essential for brain function. 
 Strategies for nanoparticle targeting to the brain rely on the presence of and nanoparticle 
interaction with specific receptor-mediated transport systems in the BBB. For example 
polysorbate 80/LDL, transferrin receptor binding antibody (such as OX26), lactoferrin, 
cellpenetrating peptides and melanotransferrin have been shown capable of delivery of a self non 
transportable drug into the brain via the chimeric construct that can undergo receptor-mediated 
transcytosis. It has been reported poly (butylcyanoacrylate) nanoparticles was able to deliver 
hexapeptide dalargin, doxorubicin and other agents into the brain which is significant because of 
the great difficulty for drugs to cross the BBB. Despite some reported success with polysorbate 
coated NPs, this system does have many shortcomings including desorption of polysorbate 
coating, rapid NP degradation and toxicity caused by presence of high concentration of 
polysorbate. OX26 MAbs (anti-transferrin receptor MAbs), the most studied BBB targeting 
antibody, have been used to enhance the BBB penetration of  lipsosomes. However, recently, Ji 
et al. demonstrated that brain uptake of lactoferrin, an iron-binding glycoprotein belonging to the 
transferrin (Tf) family, is twice that of OX26 and transferrrin in vivo. It is possible soon we will 
see these BBB specific molecules used for targeting nanoparticles to the brain 22
. 
1.9. APPLICATION OF NANOPARTICLES IN DIFFERENT FIELD 
 Nanomedicines: Nano drugs medical devices, Tissue engineering etc. 
 Chemical and cosmetics: Nano scale chemicals and compounds, paints, coating etc. 
 Material: Nanoparticles, carbonnanotubes, biopolymer, paints, coating. 
 Food sciences and: Processing, nutraceticalsfood, nanocapsules, water air. 
 Environment energy: purification filters,fuelcells,photovoltaic. 
 Military and Energy: Biosensor,weapons,sensory enhancement.  
 Electronic: Semi conductorchips,memorystorage,photonica,optoelectronics. 
 Scientific Tools:Atomic force, microscopic scanning and tunnelling microscope 
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1.10. DISEASE OVER REVIEW –HYPERTENSION23 
The drugs used to lower BP in Hypertension is a very common disorder,particularly as 
middle age. It is not a disease in itself, but is an important risk factor for cardiovascular mortality 
and morbidity. For practical purposes hypertension could be that level of BP at or above which 
long-term antihypertensive treatment will reduce cardiovascular mortality. The JNC (2003) and 
WHO-ISH guidelines (2003) have defined it to be 140 mm Hg systolic and 90 mm Hg 
diastolic,though risk appear to increase even above 120/80 mm Hg. Epidemiological studies have 
confirmed that higher pressure (systolic or diastolic or both) greater risk of cardiovascular 
disease. 
1.11. TREATMENT OF HYPERTENSION 
The aim of antihypertensive therapy is to prevent morbidity and mortality associated with 
persistently raised BP by lowering it to an acceptable level, with minimum inconvenience to the 
patient. Both systolic and diastolic BP predict the target organ damage and complications such 
as: 
(a) Cerebro vasculardisease, transient schaemic attacks, storke, 
(b) Hypertension heart disease –left ventricular hypertrophy, CHF. 
(c) Glomerulopathy, Renal failure. 
(d) Coronary artery disease (CAD), angina, myo-cardialinfaraction, sudden cardiac death. 
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1.12. Future opportunities and challenges 
           Nanoparticles have already been applied as drug delivery systems with great success. 
Nanoparticles provide massive advantages regarding drug targeting, delivery and with their 
potential for combine diagnosis and therapy and one of the major tools in Nanomedicine. These 
are many technical, challenges in developing the following techniques:- Virus-like systems for 
intracellular systems, Architecting of biomimetic polymers, control of sensitive drugs, functions 
(of active drug targeting, bioresponsive triggered systems, systems interacting with me body 
smart elivery), nanochips for nanoparticle release, carriers for advanced polymers for the 
delivery of therapeutic peptide / proteins. Drug delivery techniques were established to deliver or 
control the amount & rate. Most major and established internal research programmes on drug 
delivery that are formulations and dispersion containing components down to nano sizes. 
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                                              2.  REVIEW OF LITERATURE   
      
Muhammed Rafeeq24 et al., (2010) formulated Isoniazid in chitosan Nanoparticles inorder 
to enhance bioavailability and to reduce dose frequency. Chitosan was dissolved in acetic acid 
aqueous solution at various concentrations Drug was dispersed in above Chitosan solution kept 
over magnetic stirrer at room temperature for a period of 30 minute. The Tripolyphosphate aqueous 
solution with various concentrations added drop wise to the above solution and followed by 
sonication for 5min. The resulting Chitosan nanoparticles suspension was centrifuged at 16,000 
rpm for 30 min. After freeze drying the Nanoparticles were collected. Zeta potential shows good 
positive potentials. It shows good encapsulation efficiency. And good release profile follows first 
order release kinetics. The optimized formulation was recommended for future studies like Nano 
dry powder preparation. 
 
          Rahul Paruchuri25 et al., (2010) formulated polylactide -o - glcolic acid (PLGA) 
nanoparticles of Irinotecan for cancer therapy. The analytical method development is carried out 
using acetonitrile and phosphate buffer saline. Different organic solvents were tried and various 
surfactants were used to optimize the nanoparticulate formulation. The size range and zeta potential 
was measured using Malvern zeta seizer. The lyophilization was carriedout using two different 
cryoprotectants. The maximum percent drug entrapment was found out to be 37.2%. The in vitro 
drug release of IRN NP was also found out using dialysis method in phosphate buffer saline pH 7.4. 
The invitro drug release showed sustained release of drug over 24 hours. Hence the IRN loaded 
PLGA nanoparticles have potential as a drug delivery system. Furthermore, they may have utility for 
site-specific drug delivery since the small size of the particles may allow their delivery to 
extravascular target sites through the leaky endothelia of inflamed and cancerous area. 
 
 
           Archana Nerella26 et al., (2014). designed and evaluated Letrozole Solid lipid nanoparticles 
(SLN) of LTZ. SLNs were prepared by hot homogenization followed by ultrasonication. Trimyristin 
was used as solid lipid core, Soyphosphatidyl choline, Tween 80 as surfactant mixture. Process and 
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formulation variables were studied and optimized. LTZ-SLN were characterized for mean particle 
size, polydispersity index (PDI) and zeta potential for all the formulations. The mean particles size, 
PDI, zeta potential and entrapment efficiency of optimized LTZ-SLN optimized formulation was 
found to be 28.54 nm, 0.162, 11.80 mV, 85.64 %, respectively. In vitro release profiles are 
performed in 0.1N HCl using modified franz diffusion cell showed controlled drug release behavior 
over a period of 24h. LTZ-SLN formulations are subjected to stability study over a period of 1 month 
in terms of particle size, zeta potential, PDI, entrapment efficiency and are found to be stable. 
Differential scanning calorimetry (DSC) and transmission electron microscopy (TEM) analysis was 
performed to characterize the state of drug, lipid modification, shape and surface morphology of 
prepared LTZ-SLN formulations. 
            
               Sovan Lal Pal27 et al., (2011) developed novel drug delivery systems using nanoparticles. 
Nanoparticles can offer significant advantages over the conventional drug delivery in terms of high 
stability, high specificity, high drug carrying capacity, ability for controlled release, possibility to use 
in different route of administration and the capability to deliver both hydrophilic and hydrophobic 
drug molecules.  
 
                Dinda28 et al., (2013) investigated Solid Lipid Nanoparticles (SLNs) are important because 
of their size and stability. SLNs have been reported as an alternative drug delivery device to 
traditional polymeric nanoparticles. SLNs are in submicron range (50-1000nm) and are composed of 
physiologically tolerated lipid components. At room temperature the particles are in solid state. They 
are made up of bio-compatible and bio-degradable materials capable of incorporating lipophilic and 
hydrophilic drugs. Paclitaxel is an effective drug against Aggressive Cancer’s because it adversely 
affect the process of cell division by preventing restructuring. The incorporating paclitaxel in SLNs 
using Glyceryl Mono-stearate (GMS) as a lipid matrix, poly-oxy ethylene  as a surfactant, soya-
lecithin as a co-emulsifier. Paclitaxel loaded SLNs are prepared by Solvent emulsification and 
evaporation method using ultra sonication and optimization of critical process variables were carried 
out to develop stable SLNs. The average particle size of SLNs was found to be 63nm ±5.77 with 
Poly dispersity index (PDI) 0.272 ± 0.02 and entrapment efficiency was found 94.58%. The stability 
studies and zeta potential were performed at refrigerated temperature (2-8C) indicating no significant 
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increase in particle size after one month storage. In-vitro release studies showed initial burst release 
followed by controlled release for 48hrs (about 73%). The release profile was fitted into Higuchi’s 
model .The drug diffuses from SLNs at a comparatively slower rate as the distance for diffusion 
increases. 
 
               Rahul Nair29 et al., (2012) prepared aqueous suspension of Solid lipid Nanoparticles 
containing Chitosan (CT) which is a biopolymer that exhibits a number of interesting properties 
which include controlled drug delivery. Carbamezapine (CBZ) is a lipophilic drug which shows it 
antiepileptic activity by inactivating sodium channels. The solid lipid Nanoparticles (SLN) of 
Chitosan-CBZ were prepared by using solvent injection method using ethanol as organic solvent. 
The prepared SLN formulations exhibited high encapsulation efficiency, high physical stability. The 
drug incorporated SLNs have demonstrated that the controlled release patterns of the drug for 
prolonged period. The prepared SLNs were characterized for surface morphology by SEM analysis, 
entrapment efficiency, zeta potential, FTIR, DSC and In-vitro diffusion studies. The hydrodynamic 
mean diameter and zeta potential were 168.7±1.8 nm and −28.9 ±2.0 mV for SLN-chitosan-CBZ 
respectively. Therefore chitosan-SLN can be good candidates to encapsulate CBZ and to increase its 
therapeutic efficacy in the treatment of Epilepsy. 
 
             
            Amalendu P Ranjan30 et al., (2012) formulated curcumin loaded poly (lactic acid-co-
glycolic acid) nanoparticles (PLGA-CURC). This improved the bioavailability of curcumin, a potent 
natural anticancer drug, making it suitable for cancer therapy. The nanoparticles formed after scale-
up process were characterized for particle size, drug loading and encapsulation efficiency, surface 
morphology, in vitro release kinetics and pharmacokinetics. Stability analysis and gamma 
sterilization were also carried out. It revealed that process scale-up is being mastered for elaboration 
to 5 g level. The mean nanoparticle size of the scaled up batch was found to be 158.5 ± 9.8 nm and 
the drug loading was determined to be 10.32 ± 1.4%. The in vitro release study illustrated a slow 
sustained release corresponding to 75% drug over a period of 10 days. The pharmacokinetic profile 
of PLGA-CURC in rats following  i.v. administration showed two compartmental model with the 
area under the curve (AUC0-∞) being 6.139 mg/L h. Gamma sterilization showed no significant 
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change in the particle size or drug loading of the nanoparticles. Stability analysis revealed long term 
physiochemical stability of the PLGA-CURC formulation. 
 
               Zahoor Ahmad31 et al., (2006) developed Alginate (a natural polymer) based 
nanoparticulate delivery system. Determination of frontline ATDs (Rifampicin, Isoniazid, 
Pyrazinamide and Ethambutol). Alginate nanoparticles were prepared by the controlled cation 
induced gelification method and administered orally to mice. The drug levels were analysed by high 
performance liquid chromatography (HPLC) in plasma/tissues. The therapeutic efficacy was 
evaluated in M. tuberculosis H37Rv infected mice. High drug encapsulation efficiency was achieved 
in alginate nanoparticles, ranging from 70%-90%. A single oral dose resulted in therapeutic drug 
concentrations in the plasma for 7-11 days and in the organs (lungs, liver and spleen) for 15 days. In 
comparison to free drugs (which were cleared from plasma/organs within 12-24 h), there was a 
significant enhancement in the relative bioavailability of encapsulated drugs. In TB-infected mice 
three oral doses of the formulation spaced 15 days apart resulted in complete bacterial clearance from 
the organs, compared to 45 conventional doses of orally administered free drugs.  
          
 
                 Anbarasan32 et al., (2011) optimized formulation and in vitro evaluated Chloroquine 
Phosphate loaded Chitosan Nanoparticles. Chloroquine loaded Chitosan–tripolyphosphate 
Nanoparticles were prepared by ionic gelation method  with variable drug to polymer ratios (1:3, 1:4, 
1:5, 1:6 and1:7). The drug follows linearity in the concentration range 5-30 µg/ml with regression 
coefficient value of 0.994. The drug content of Nanoparticles increases on increasing the polymer 
concentration up to a particular level. Entrapment efficiency of 92.87% was achieved with drug to 
polymer ratio 1:6. In-vitro release of Chloroquine Phosphate from Chitosan Nanoparticles was 
85.13% within 24 h. TEM image indicates that the nanoparticles have a discrete spherical structure 
and particle size was in the range nanometer. FTIR studies show the evidence of cross linking 
between positively charged amino group of Chitosan and negatively charged Phosphate group of 
TPP (TriPolyPhosphate) without any significant interaction between Chloroquine Phosphate and 
Chitosan Nanoparticles after encapsulation. Good stability is observed at refrigeration condition 
compared to other temperature conditions during eight weeks of storage.   
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               Partha Saha33 et al., (2010) developed Ampicillin trihydrate-loaded chitosan nanoparticles 
were prepared by ionic gelation method with the aid of sonication. Parameters such as the zeta 
potential, polydispersity, particle size, entrapment efficiency and in vitro drug release of the 
nanoparticles were assessed for optimization. The antibacterial properties of the nanoparticle 
formulation were evaluated and compared with that of a commercial formulation. Scanning electron 
microscopy revealed that the nanoparticles were in the nanosize range but irregular in shape. 
Concentrations of 0.35 %w/v of chitosan and 0.40 %w/v sodium tripolyphosphate (TPP) and a 
sonication time of 20 min constituted the optimum conditions for the preparation of the 
nanoparticles. In vitro release data showed an initial burst followed by slow sustained drug release. 
The nanoparticles demonstrated superior antimicrobial activity to plain nanoparticles and the 
reference, due probably to the synergistic effect of chitosan and Ampicillin trihydrate. Modified ionic 
gelation method can be utilized for the development of chitosan nanoparticles of Ampicillin 
trihydrate. Polymer and crosslinking agent concentrations and sonication time are rate-limiting 
factors for the development of the optimized formulation. The chitosan nanoparticles developed 
would be capable of sustained delivery of Ampicillin trihydrate.   
 
           
            Tamizhrasil34 et al., (2009) prepared and evaluated polymethacrylic acid nanoparticles 
containing lamivudine in different drug to polymer ratio by nanoprecipitation method. SEM 
indicated that nanoparticles have a discrete spherical structure without aggregation. The average 
particle size was found to be 121.8- 403.4 nm. The particle size of the nanoparticles was gradually 
increased with increase in the proportion of polymethacrylic acid polymer. The drug content of the 
nanoparticles was increasing on increasing polymer concentration up to a particular concentration. 
No appreciable difference was observed in the extent of degradation of product during 60 days in 
which, nanoparticles were stored at various temperatures. FT-IR studies indicated that there was no 
chemical interaction between drug and polymer and stability of drug. The in-vitro release behaviour 
from all the drug loaded batches was found to be zero order and provided sustained release over a 
period of 24 h. The developed formulation overcome and alleviates the drawbacks and limitations of 
lamivudine sustained release formulations and could possibility be advantageous in terms of 
increased bioavailability of Lamivudine. 
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                Shagufta Khan35 et al., (2012) formulated Dithranol in the form of solid lipid 
nanoparticle. Solid lipid  nanoparticles of dithranol were obtained by adaption of lipid dispersion 
method. Solubility study, partition coefficient determination, UV analysis, HPLC study, FTIR study 
were also performed. After the preformulation studies loaded solid lipid nanoparticles was also 
prepared.  
 
             
               Priyanka patil36 et al., (2014) optimized and evaluated Doxorubicin loaded spray dried 
chitosan nanocarriers as a sustained release by using ionotropic gelation technique. Spray-drying 
becomes a good technique to improve the stability of colloidal nanoparticles. The influences of the 4 
decision variables (i.e. chitosan concentration, cross-linking concentration, stirring speed, stirring 
time on the mean particle size, Entrapment efficiency, in-vitro release a four factorial / two level 
experimental design was carried out by the design expert software. The prepared nanoparticles were 
evaluated for particle size, scanning electron microscopy (SEM), percentage yield, drug entrapment, 
zeta potential, Differential scanning calorimetry and in-vitro release study. Among all batches have 
high drug loading 66% and  particle size 126-1392 nm. Based on in-vitro release study formulations 
show biphasic pattern characterized by initial burst release followed by a slower and sustained 
release. 
 
               Vivek Kumar Gupta37 et al., (2010) investigated the nanoparticle formulations enhanced 
dissolution properties and the potential for intracellular drug delivery. Specifically, pure drug 
nanoparticles, polymeric nano- particles and polyelectrolyte complexes offer some encouraging 
results for delivering drugs to various organs and through various routes. Traditional techniques such 
as spray drying and grinding, and more recent advances in supercritical fluid extraction, 
precipitation, and double solvent evaporation have been employed to produce nanoparticle 
formulations for delivery of hydrophilic & hydrophobic drugs here, the benefits of nanoparticle 
formulations and current progress are compared in light of the practical encumbrances of producing 
formulations, and possible toxicological effects of these materials. 
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               Srinivas38 et al., (2012) prepared controlled release formulation of Moxifloxacin 
Hydrochloride ocular nanoparticles. The nanoparticles were prepared by solvent displacement 
method using Eudragit RL 100 as a polymer. Different formulations were prepared by varying the 
ratios of drug and polymer and varying the ratios of organic and aqueous phase. The formulations 
were evaluated in terms of particle size, FTIR, drug entrapment efficiency and in vitro drug release 
profile was examined. The anti bacterial activity against gram positive and gram negative bacteria 
were determined. In vivo studies were carried out by Draize test. The mean particle size for drug 
loaded formulations was found to be below 200 nm. The zeta potential remained in the range of 
positive values for all batches +10 mV to +40mV. The formulation possesses good antibiotic activity 
against Escherichia coli, Bacillus subtilus and Staphylococcus aureus microorganism and no eye 
irritation on in-vivo testing. 
                
              
                Adlin Jino Nesalina39 et al., (2012) formulated zidovudine loaded nanoparticles were 
prepared by ionic gelation of chitosan with tripolyphosphate anions (TPP). Nanoparticles of different 
core: coat ratio were formulated and evaluated for process yield, loading efficiency, particle size, 
zeta potential, in vitro drug release, kinetic studies and stability studies. The chitosan nanoparticles 
have a particle diameter ranging approximately 342–468 nm and a zeta potential 20.4 to 37.08 mV. 
There was a steady increase in the entrapment efficiency on increasing the polymer concentration in 
the formulations. The in vitro release behaviour from all the drug loaded batches were found to 
follow first order and provided sustained release over a period of 24 h. No appreciable difference was 
observed in the drug content of product during 60 in which nanoparticles were stored at 4˚C and 
room temperature. According to the data obtained, this chitosan- based delivery system opens new 
and interesting perspectives as drug carriers. 
 
                
                Mohamed Ali Attia Shafie40 et al., (2013) formulated and investigated mucoadhesive 
chitosan-sodium alginate nanoparticles as new vehicle for the prolonged topical ophthalmic delivery 
of Betamethasone sodium phosphate. Ionotropic gelation method was used to produce 
Betamethasone loaded chitosan alginate nanoreservoir system. The effect of changing different 
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formulation parameters (pH of chitosan solution, sodium alginate concentration, calcium chloride 
concentration, chitosan concentration, drug concentration and the addition of tween 80) on the 
physicochemical properties and in vitro release of the drug loaded nanoparticles was studied. The 
mean particle size ranged from 16.8 to 692 nm and the zeta potential generally ranged from +18.49 
to +29.83 mV depending on the formulation conditions. The highest encapsulating efficiency 
obtained was 64%. In vitro release studies showed an initial burst release of the drug followed by 
slow sustained release over 24, 48 or 72 hours depending on the formulation parameters. The in vivo 
studies carried out for two selected formulations showed the release of 84%, 59.5% of the drug over 
12 hours showed good stability at both 25°C and 40°C as the drug content was within the accepted 
range, the pH was (5–7) and the mean particle size for both formulations over the three months was 
still interesting for ophthalmic application. chitosan alginate nanoparticles would be a promising 
system for the sustained release delivery of Betamethasone sodium phosphate to the posterior 
segment of the eye. 
 
                
               Sagar41 et al., (2013) formulated and evaluated intranasal mucoadhesive nanoparticles of 
Rizatriptan benzoate (RZB). loaded Chitosan (CS) nanoparticles were prepared by ionic gelation of 
CS with tripolyphosphate anions (TPP).  The ionic gelation method is easy, reproducible and led to 
efficient entrapment. Some process variables like effect of CS concentration, TPP concentration were 
also evaluated with respect to % entrapment. The maximum entrapment efficiency and drug content 
was 69.1% and 60.63%, shown by optimized formulation. Particle size of optimized formulation was 
0.248 µ shown by Zetasizer. Spray drying of optimized formulation was carried out and process yield 
was determined, which was found to be 38.78%. Spray dried nanoparticles was spherical in shape 
and varied surface roughness was found in Scanning electron microscopy (SEM) images. Spray dried 
nanoparticles were evaluated by Differential scanning calorimetry (DSC), X-ray diffraction (XRD) 
pattern to study crystalline/amorphous nature of nanoparticles, and mucoadhesive test. The 
percentage mucoadhesion on nasal mucosa of goat was found to be 29.4%. The release behavior of 
CS nanoparticles were evaluated in phosphate buffer pH 6.5, revealed that RZB loaded CS 
nanoparticles is most suitable for intranasal drug delivery.      
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           Panakanti Pavan Kumar42 et al., (2012) formulated Atorvastatin (ATRS) loaded solid lipid 
nanoparticles by hot homogenization fallowed by ultrasonication technique, and optimization of 
formulation and process parameters to formulate preferred SLN dispersions. The effects of 
composition of lipid materials, surfactant mixture and sonication time on particle size, PDI, zeta 
potential, drug entrapment efficiency, and in vitro drug release behavior were investigated  The mean 
particles size, PDI, zeta potential and entrapment efficiency of optimized formulation (A5) was 
found to be 50.0± 6.12 nm, 0.08±0.011,10.40± 4.68mV, 88.7± 6.08 % respectively. Shape and 
surface morphology was determined by Transmission Electron Microscopy (TEM) which revealed 
fairly spherical shape of nanoparticles. The in-vitro drug release study demonstrated that ATRS-SLN 
It possessed controlled drug release over a period of 24 hrs than dispersion of pure drug. Stability 
studies performed on the selected formulations revealed that there was no physical instability of the 
developed formulation for a period of 3 months at room and refrigerated temperatures.    
 
            
                  Amar singh43 et al., (2011) prepared Losartan potassium loaded chitosan nanoparticles 
by ionic gelation of chitosan with tripolyphosphate ions. Nanoparticles of different core coat ratio 
were formulated and evaluated for drug content, loading efficiency, particles size, zeta potential, 
invitro drug release and stability studies. Scanning electron microscopy indicated that the nano-
particles were found to be in nanometer range and showed ideal surface morphology. Differential 
scanning calorimetry analysis indicated that there were no chemical interactions between drug and 
polymer and stability of drug. Invitro release behavior from all the drug loaded batches were found to 
follow zero order and provided sustained release over a period of 24 hrs. The developed formulation 
overcomes and could possibility be advantageous in terms of sustained release dosage forms of 
Losartan potassium.  
 
            
                Yukio44 et al., (2012) designed novel nanoparticles, which possess nitroxide radicals in the 
core for novel bioimaging and nanotherapy. Nitroxide radical containing nanoparticles (RNP) shows 
high safety, long blood circulation, magnetic resonance imaging and ESR imaging sensitive 
character and efficient therapeutic effects to several diseases such as cerebral and renal ischemia 
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reperfusions, ulcerative colitis and Alzheimer’s disease models. RNPs are, thus, promising as new 
nanotherapeutic materials. 
                                                                                                                                                                                                                                                             
        
              Magdalena Stevanovi45 et al., (2009) preparaed Poly (lactide-co-glycolide) based micro 
and nanoparticles for the controlled drug delivery. Polymers like polylactides (PLA), polyglycolides 
(PGA), (lactide-co-glycolides) (PLGA), are approved by the World Health Organization (WHO) and 
Food and Drug Administration (FDA) as materials that can be used in medicine and pharmacy. 
Owing to their biodegradable nature, polymer materials, such as copolymer poly (DL-lactide-co-
glycolide), are widely used in various medical applications; controlled release of delivering drugs, 
carriers in the tissue engineering, fixation of bone fractures,  strings, etc.  
 
Ping Lil46 et al., (2008) formulated chitosan–alginate nanoparticles by ionotropic pre-
gelation of an alginate core followed by chitosan polyelectrolyte complexation. Morphology and 
structure characterization of nanoparticles by transmission electron microscope (TEM) and Fourier 
transform infrared spectra (FTIR), respectively. Nifedipine released from chitosan–alginate 
nanoparticles was 26.52% at pH1.5, 69.69% at pH6.8 and 56.50% at pH 7.4 within 24hrs. The 
release of nifedipine from nanoparticles was pH-responsive. Quick release occurred in simulated 
intestinal fluid (SIF, pH6.8) and phosphate buffer solution (pH7.4), while the release was slow in 
simulated gastric fluid (SGF, pH1.5). The release profile was characterized by an initial burst effect 
in three media, followed by a continuous and controlled release phase, the drug release mechanism 
from polymer was due to Fickian. 
 
  
              Mariangela de Burgos47 et al., (2011) investigated physicochemical characterization and 
invivo ACE inhibition evaluation of seven Captopril from cyclodextrin nanoparticles CAP/CD 
complexes. The physicochemical analysis demonstrated complete Amorphization and complexation 
between CAP and CDs, indicating the substitution of water molecules inside the CD cavity with 
CAP. During the infusion of angiotensin I, the administration of all CAP/CD complexes induced a 
reduction in mean arterial pressure similar to that observed upon CAP administration. The 
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nanoparticles obtained by the kneading method showed a potent and long-lasting inhibitory activity 
(∼22 hrs) on the angiotensin I pressor effect. The inclusion complex of CAP and CD can function as 
a novel antihypertensive formulation that may improve therapeutic use of CAP by reducing its oral 
dose administration to once per day, thus providing better quality of life for almost 25% of the 
world’s population who suffer from hypertension.  
    
  
             Catarina pinto reis48 et al., (2006) formulated the drug-loaded polymeric nanoparticles, 
because they show promise as drug delivery systems as a result of their controlled and sustained 
release properties, subcellular size, and biocompatibility with tissue and cells. Several methods to 
prepare nanoparticles have been developed during the last two decades, classified according to 
whether the particle formation involves a polymerization reaction or arises from a macromolecule or 
preformed polymer. the most important preparation methods are described, specially those that make 
use of natural polymers. 
 
 
            Lulina Florentina49 et al., (2012) studied the drug carriers were tested in the controlled drug 
release process and the influence of the silica pore morphology and geometry on drug release profiles 
the  invitro release studies and to evaluate the kinetic release mechanism, the Korsmeyer and Peppas 
equation was used. The obtained drug delivery system based on MgO–SBA-15 matrix exhibits 
exciting structural features and is therefore promising for its use as antihypertensive drug delivery 
system, having potential therapeutic benefits resulting in safe and effective management of Captopril 
and  adsorption and invitro release. 
    
 
  Mohammed M. Rahman50 et al., (2013) prepared Nebivolol drug based on Silver oxide 
nanoparticles by a wet chemical method. The morphological, structural, elemental, and optical 
properties of nanoparticles are investigated by UV/vis. and FT-IR spectroscopy, powder X-ray 
diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and field-emission scanning electron 
microscopy (FESEM) etc. fabricated on a glassy carbon electrode (GCE) to give a fast response 
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towards Nebivolol drug. The Nebivolol drug sensor also displays good sensitivity and long-term 
stability, and enhanced electrochemical I-V response.  
 
 
 Vikram S Shenoy51 et al., (2013) investigated the formulation and invitro anticancer 
activities of solid lipid nanoparticles (SLNs) of 5-Fluorouracil (5-FU) using glyceryl monostearate 
(GMS) and cetyl palmitate (CP) by hot homogenization method. The lipids were selected based on 
the partition coefficient of 5-FU in lipids. The optimized nanoparticles were characterized for their 
zeta potential, morphology, release kinetics, and anticancer activity. Higher entrapments were 
achieved using a combination of emulsifiers. The zeta potential of the optimized CP and GMS SLN 
formulation were −8.26 and −9.35 mV, respectively. Both the optimized formulations were spherical. 
Subtoxic concentration of 5-FU-loaded CP SLNs (0.12 μg/mL) possessed comparable 
antimigrational activity, colony inhibition activity, and cytopathic as that of 5-FU solution effects. 
The encapsulating 5-FU in CP would be a promising delivery system for delivering 5-FU.   
  
  Suganeswari52 et al., (2011) prepared and evaluated nanoparticles containing hypolipidaemic 
drug (Atorvastatin calcium: D1N) antihypertensive agent (Amlodipine besylate D2N) loaded by 
nanoprecipitation method using tribloere polymeric stabilizer (Pluronic F68). Biodegradable 
nanoparticles formulated from poly (D,L-lactide-co-glycolide) (PLGA) polymers are being 
extensively investigated for various drug delivery applications. Nanoparticles using PLGA polymers 
were formulated using nanoprecipitation technique, and were characterized for size, drug loading, 
and invitro release. Atorvastatin calcium is a second generation 3- hydroxy-3-methyl glutaryl CoA 
reducatase inhibitor approved for clinical use as a lipid lowering agent. Atorvastatin calcium, the 
world’s best selling drug is associated with poor oral bioavailability (12%) and serious adverse 
effects like rhabdomyolysis on chronic administration. Side effect of Atorvastatin was reduced 60% 
by combining with amlodipine. The Amlodipine has potency to promote the activity of atorvastatin. 
A biodegradable nanoparticulate approach was introduced here with a view to improving the efficacy 
and safety of Atorvastatin calcium. Particulate systems like nanoparticles have been used as a 
physical approach to alter and pharmacodynamic properties of various types of drug molecules. The 
nanoparticluate suspension of Amlodipine is to improve its absorption rate and therapeutic efficacy. 
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Subramanian53 et al., (2012) formulated and evaluated of Ofloxacin nanoparticles by 
emulsion Polymerization method to release the drugs in the vicinity of the target tissue. 
Nanoparticles are solid colloidal particles with diameter ranging from 1nm – 1000nm. Ofloxacin is a 
first generation fluroquinolones antimicrobials it active against gram negative bacteria. Ofloxacin 
nanoparticles was prepared by emulsion polymerization method by using Eudragit S-100 polymer as 
a continuous phase for four different ratios such as (Drug: Polymer) (1:1), (1:2), (1:3) and (1:4). The 
polymer was dissolved in Dichloromethane and the solution was emulsified with the aqueous 
solution of Ofloxacin containing 2% Tween 80 by stirring for 1 hrs at 15oC with the aid of 
mechanical stirrer at 3000rpm.The nanoparticles was formed and separated by centrifugation. The 
formulated nanoparticles are evaluated for external morphological studies using scanning electron 
microscope. The invitro release study was performed in phosphate buffer pH 7.4. The IR study 
reveals that in no major shifting as well as non less of functional groups peak between the drug, 
polymer and drug loaded nanoparticles. The invitro release study showed that the formulation ratio 
(1:1) gives the better sustained effect over 88.13 % of drug was released at 8 hrs. the Ofloxacin 
nanoparticles are suitable candidates to produce good antibiotic prolong action of the drug 
nanoparticles. 
 
 
 Adlin Jino Nesalin54 et al., (2009) developed Flutamide nanoparticles formulated using 
chitosan polymer by ionic gelation technique. Nanoparticles of different core coat ratio were 
formulated and analyzed for total drug content, loading efficiency, particle size and invitro drug 
release studies. The nanoparticles prepared with chitosan in the core: coat ratio 1:4 gives better 
sustained release for about 12 hrs as compared to other formulations. 
 
 
Karthikeyan55 et al., (2013) formulated Stavudine nanoparticles specially designed to 
release the drug in the vicinity of target sites. The surface modified Stavudine entrapped low 
molecular weight chitosan (CS) nanoparticles as potential drug delivery system for anti-HIV 
chemotherapy. The particle size and the surface morphology results revealed that Stavudine 
nanoparticles (SNPs) were smooth spheroidal with a size ranging from 260 nm-632 nm. The drug 
entrapment efficiency was found to be near 83%. In vitro release studies revealed that the rate of 
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drug release from SNP5 was 93% in 24 hrs. Release of drug follows zero order and show sustained 
release behavior. Koresmeyer  models shows that the drug follow non-Fickian transport as the value 
of n>0.5. The results suggest that chitosan polymer based nanoparticulate formulations are potential 
means to achieve release of stavudine for the prolonged period of time for effective therapy.  
 
 
Selvakumar56 et al., (2009) prepared the nanoparticles of Carvedilol with  Eudragit E 100 
were prepared by the nanoprecipitation method using Polymeric stabilizer Poloxamer 407. 
Nanoparticles of Carvedilol were obtained with high encapsulation efficiency. The particles were 
characterized for particle size by photon correlation spectroscopy and transmission electron 
microscopy. The invitro release studies were carried out by USP Type II apparatus in SGF without 
enzyme (pH 1.2).The particle size of the prepared nanoparticles ranged from 190 nm – 270 nm. 
Nanoparicles of carvedilol were obtained with high encapsulation efficiency (85-91%). The drug 
release from the carvedilol nanoparticles showed within 5 minutes. The feasibility of formulating 
carvedilol – loaded Eudragit E 100 nanoparticles for the treatment of hypertension. 
 
 
  Riddhi Dave Patel57 et al., (2012) investigated cryoprotectant on lyophlisation of 
Doxorubicin–Hcl loaded chitosan  nanoparticles.  Nanoparticles stability of formulation is very poor 
when it is in form of aqueous suspension. So, Freeze-drying becomes a good technique to improve 
the stability of colloidal nanoparticles. Shelf life of colloidal particles can be enhanced by 
lyophilisation by several folds. cryoprotectants are added during lyophilisation to protect the 
intactness of particles in injectable products. The role and influence of type of cryoprotectant and its 
concentration in the lyophilization of Doxorubicin- HCl Chitosan Nanoparticles. 
 
 
Jameel Ahmed58 et al., (2012) designed Repaglinide loaded solid lipid nanoparticles design 
and characterization solid lipid nanoparticles (SLNs) have attracted increasing attention during recent 
years.  prolonged release SLNs of repaglinide (RPG) for oral delivery and to improve bioavailability 
of RPG. SLNs were formulated using tristearin as the lipid core and poloxamer 188 and egg lecithin 
as a mixture of emulsifiers by microemulsion method. Formulations were characterized by infrared 
spectroscopy (FTIR), differential scanning calorimetry (DSC), particle size analysis, entrapment 
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efficiency , scanning electron microscopy (SEM), short term storage stability at 40 ± 2 °C/75 ± 5% 
RH and invitro release studies. IR and DSC studies showed that when the drug was incorporated into 
the solid matrix there was no possible interaction between drug and lipid carrier.Variables such as 
concentrations of lipid and emulsifiers and stirring speed showed great impact on particle size and 
entrapment efficiency Optimized SLNs with 5% lipid, 2% emulsifier mixture and stirring speed of 
21,500rpm showed mean particle size of 440 nm and EE% 74.66. SEM confirms that the SLNs are in 
circular shape.   
 
Hequn59 et al., (2013)  studied the invivo evaluation of Doxorubicin loaded BSA 
nanoparticles with folic acid modified dextran surface biocompatible and biodegradable doxorubicin 
loaded nanoparticles with targeting ability were prepared from BSA–dextran–folic acid conjugate via 
a pH adjustment and heating process. The BSA–dextran–folic acid conjugate was produced by an 
esterification reaction between folic acid and dextran and then the maillard reaction between the 
modified dextran and BSA. The nanoparticles have a size about 90 nm and excellent dispersibility at 
pH 7.4 aqueous solution. The Doxorubicin loading efficiency and loading amount of the 
nanoparticles are larger than 90% and 14%, respectively. The antitumor activity and toxicity of the 
nanoparticles were evaluated through murine ascites hepatoma H22 tumor-bearing mice. 
Importantly, the nanoparticles can decrease the toxicity of Doxorubicin that results in a significant 
increase of the average life time in comparison with the free Doxorubicin as well as the nanoparticles 
without folic acid. 
 
 
  Vyjayanthimala60 et al., (2014) formulated and evaluated chitosan Nanoparticles of 
Zidovudine for antiviral therapy. Nanoparticles of Zidovudine were prepared using chitosan, liquid 
paraffin and Tween-20 using Emulsion droplet coalescence method. The concentration of the 
polymer Chitosan was selected based on the results on preliminary screening. The nanoparticles 
prepared were evaluated for morphology, loading efficiency and invitro release. The particle shape 
and morphology of the prepared Zidovudine nanoparticles were determined by SEM analysis. The 
amount of Zidovudine entrapment in the nanoparticles was calculated by the difference between the 
total amount of drug added to the nanoparticle and the amount of non-entrapped drug remaining in 
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the aqueous supernatant. A Franz diffusion cell was used to monitor Zidovudine release from the 
nanoparticles. Drug  released 75.89% of Zidovudine in 12 hrs with a burst drug release nearly 
14.86% of drug within the initial 1 hrs. Among the four formulations  showed maximum drug release 
in 12 hrs diffusion study and good entrapment efficiency. In-vitro antiviral study revealed that the 
formulated nanoparticles were found to have good viral activity. 
 
  
Kumar Vikas61 et al., (2011) investigated on novel drug delivery system for delivery of 
antihypertensive drugs novel drug delivery systems present an opportunity for formulation scientists 
to overcome the many challenges associated with antihypertensive drug therapy, thereby improving 
the management of patients with hypertension. Currently available Anti-hypertensive drugs can be 
classified into these categories: ACEinhibitors, angiotensin antagonist, calcium channel blocker, 
diuretics, central sympathomimetics, a- adernergic blocker, vasodilator, â-adernergic blocker. Most 
of these drugs bear some significant drawback such as relatively short half-life, low bioavailability, 
poor permeability and undesirable side effects. efforts have been made to design drug delivery 
systems for antihypertensive drugs to a reduce the dosing frequency, increase the bioavailability, 
deliver them to the target cells selectively with minimal side effects. The various anti hypertensive 
drug delivery systems that have been developed for achieving sustained drug release kinetics,and for 
addressing formulation difficulties such as poor solubility, stability and drug entrapment. The 
physicochemical lproperties and the invitro/ invivo performances of various system such as such a 
sustained release tablets, ceramic implants, nanoparticles, nanocontainers, liposomes, emulsomes, 
aspasomes, microemulsions,nanopowders and Pheroid TM are summarised. This review highlights 
the significant potential that novel drug delivery system have for the future effective treatment of 
hypertensive. 
 
 
     Kumar62 et al., (2007) developed and evaluated a Nitrendipine loaded solid lipid 
nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Nitrendipine is an 
antihypertensive drug with poor oral bioavailability ranging from 10 to 20% due to the first pass 
metabolism. For improving the oral bioavailability of nitrendipine, nitrendipine loaded solid lipid 
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nanoparticles have been developed using triglyceride (tripalmitin), monoglyceride (glyceryl 
monostearate) and wax (cetyl palmitate). Poloxamer 188 was used as surfactant. Hot homogenization 
of melted lipids and aqueous phase followed by ultrasonication at temperature above the melting 
point of lipid was used to prepare SLN dispersions. SLN were characterized for particle size, zeta 
potential, entrapment efficiency and crystallinity of lipid and drug. invitro release studies were 
performed in phosphate buffer of pH 6.8 using Franz diffusion cell. Pharmacokinetics of nitrendipine 
loaded solid lipid nanoparticles after intraduodenal administration to conscious male wistar rats was 
studied. Bioavailability of nitrendipine was increased three- to four-fold after intraduodenal 
administration compared to that of nitrendipine suspension. solid lipid nanoparticles as carriers for 
improving the bioavailability of lipophilic drugs such as nitrendipine by minimizing first pass 
metabolism. Nitrendipine is an antihypertensive drug with poor oral bioavailability ranging from 10 
to 20% due to the first pass metabolism. For improving the oral bioavailability of nitrendipine, 
nitrendipine loaded solid lipid nanoparticles have been developed using triglyceride (tripalmitin), 
monoglyceride (glyceryl monostearate) and wax (cetyl palmitate). Poloxamer 188 was used as 
surfactant. Hot homogenization of melted lipids and aqueous phase followed by ultrasonication at 
temperature above the melting point of lipid was used to prepare SLN dispersions. Pharmacokinetics 
of nitrendipine loaded solid lipid nanoparticles after intraduodenal administration to conscious male 
wistar rats was studied. Bioavailability of nitrendipine was increased three- to four-fold after 
intraduodenal administration compared to that of nitrendipine suspension. 
  
Krishna sailaja63 et al., (2011) prepared a nanoparticle using natural polymer and their 
application targeting delivery of drugs to the diseased lesions is one of the most important aspects of 
drug delivery system. The invivo to protect the drug entity in the systemic circulation, restrict access 
of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to the site of 
action. Various polymers have been used in the formulation of nanoparticles for drug delivery 
research to increase therapeutic benefit, while minimizing side effects. In order to see functionality 
and toxicity of nanoparticles in various food and drug applications, it is important to establish 
procedures to prepare nanoparticles are controlled size. Natural polymers have been classified into 
polysaccharides and proteins. Chitosan is a natural polymer obtained by deacetylation of chitin. After 
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cellulose chitin is the second most abundant polysaccharide in nature. It is biologically safe, 
nontoxic, biocompatible and biodegradable polysaccharide. Chitosan nanoparticles have gained more 
attention as drug delivery carriers because protein nanoparticle are nontoxicity, stability for long 
duration,non‐antigen also posseses biodegradability. In fact protein is biopolymer, which is 
commonly used for preparation of nano structured molecules for drug delivery.  
 
 Anjali Goel64  et al.,(2012)  synthesized colloidal iridium nanoparticles  by chemical 
oxidation method with different surfactants like poly vinyl pyrrolidone (PVP), poly vinyl alcohol 
(PVA) and poly oxyethylene lauryl ether (POLE). It was found that shape and size of Ir-nano 
particles resulted were related to kind of capping agent (surfactant) used. The characterization of the 
synthesized nano particle has been carried out by UV-vis, X-ray diffraction (XRD), FT-IR, scanning 
electron microscopy (SEM) and transmission electron microscopic (TEM) techniques. UV-vis and 
FT-IR con- firm the oxidation of IrCl3 into IrO2 while XRD con-firms the amorphous nature of the 
iridium nanoparticles synthesized. The morphology and size of the particle were confirmed by TEM.  
 
 
            Tapas Kumar Kundu 65 et al., (2011) prepared ZnO nanoparticles in support of poly(vinyl 
alcohol) (PVA) molecules. PVA molecules offer plenty of active OH groups and a metal ion-
polymer complex is formed via a kind of ligand reaction.The particle sizes lie in the range of 23 nm - 
43 nm. The Electronparamagnetic resonance (EPR) spectra of the powders are characterized by a 
broad resonance peak owing to presence of zn+ defects in the specimens.The nanopowders show an 
intense violet emission along with the emission in blue and green band. In comparison, ZnO 
specimens having micron sized grain which are prepared without using PVA do not show any 
emission with significant intensity. zn+ defects play a role in improving the optical emission of ZnO 
nanoparticles prepared by this method.  
 
 
 Zhang66 et al., (2010) developed nanoparticles for antimicrobial drug delivery Numerous 
antimicrobial drugs have been prescribed to kill or inhibit the growth of microbes such as bacteria, 
fungi and viruses. Even though the therapeutic efficacy of these drugs has been well established, 
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inefficient delivery could result in inadequate therapeutic index and local and systemic side effects 
including cutaneous irritation, peeling, scaling and gut flora reduction. Nanostructured biomaterials, 
nanoparticles in particular, have unique physico chemical properties such as ultra small and 
controllable size, large surface area to mass ratio, high reactivity, and functionalizable structure. 
Encapsulation of antimicrobial drugs in nanoparticle systems has emerged as an innovative and 
promising alternative that enhances therapeutic effectiveness and minimizes undesirable side effects 
of the drugs. the current progress and challenges in synthesizing nanoparticle platforms for 
delivering various antimicrobial drugs are reviewed.  
 
Che-ming67 et al., (2010) investigated that nanoparticle assisted combination therapies for 
effective cancer treatment combination chemotherapy and nanoparticle drug delivery are two areas 
that have shown significant promise in cancer treatment. Combined therapy of two or more drugs 
promotes synergism among the different drugs against cancer cells and suppresses drug resistance 
through distinct mechanisms of action. Nanoparticle drug delivery, on the other hand, enhances 
therapeutic effectiveness and reduces side effects of the drug pay loads by improving their 
pharmacokinetics. These two active research fields have been recently merged to further improve the 
efficacy of cancer therapeutics. the recent efforts in developing nanoparticle platforms to 
concurrently deliver multiple types of drugs for combination chemotherapy. the challenges and 
design specifications that need to be considered in optimizing nanoparticle-based combination 
chemotherapy. 
 
 
 
  Afifa Bathool68 et al., (2012) developed  Atorvastatin calcium chitosan  loaded nanoparticles 
prepared by solvent evaporation method for sustained release. Low oral bioavailability of 
Atorvastatin calcium (14%) due to an extensive high first-pass effect makes it as prime target for oral 
sustained drug delivery. Weighed amount of drug and polymer were dissolved in suitable organic 
solvent DMSO and 2% acetic acid as an organic phase. This solution is added drop wise to aqueous 
solution of Lutrol F68 and homogenized at 25000rpm followed by magnetic stirring for 4hrs. 
Nanoparticles were evaluated for its particle size, scanning electron microscopy (SEM), Fourier-
Transform infrared spectroscopy (FTIR), percentage yield, drug entrapment and for invitro release 
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kinetics. Among the four different ratios, 1:4 ratio showed high drug loading and encapsulation 
efficiency. SEM studies shows that prepared nanoparticles were spherical in shape with a smooth 
surface. Particle size of prepared nanoparticles was found to be in range between 142 nm to 221 nm. 
FTIR and DSC shows drug to polymer compatibility ruling out any interactions.  invitro release 
study showed that the drug release was sustained up to 7 days. Hence, prepared nanoparticles proved 
to be promising dosage form for sustained drug delivery of Atorvastatin reducing dosing frequency, 
thus increasing the patient compliance. 
 
 Vivek Kumar Gupta69 et al., (2010) formulated hydrophilic & hydrophobic drugs 
nanoparticle  have many advantages over traditional dosage forms, such as enhanced dissolution 
properties and the potential for intracellular drug delivery. Specifically, pure drug nanoparticles, 
polymeric nano-particles and polyelectrolyte Traditional techniques such as spray drying and 
grinding, and more recent advances in supercritical fluid extraction, precipitation, and double solvent 
evaporation have been employed to produce nanoparticle formulations for delivery of hydrophilic & 
hydrophobic drugs here, the benefits of nanoparticle formulations and current progress are compared 
in light of the practical encumbrances of producing formulations, and possible toxicological effects 
of these materials. 
 
 
 Peng Guo70 et al., (2012) prepared amorphous hydrophobic drug nanoparticles by 
nanoporous membrane extrusion method for formulating hydrophobic drugs into nanoparticulate 
form in a scalable and inexpensive manner. The nanoporous membrane extrusion (NME) method 
was used to prepare hydrophobic drug nanoparticles. NME is based on the induced precipitation of 
drug-loaded nanoparticles at the exits of nanopores. Three common hydrophobic drug models 
(silymarin, beta carotene and butylated hydroxytoluene) were tested. The authors carefully 
investigated the morphology, crystallinity and dissolution profile of the resulting nanoparticles.  
Using NME, the authors successfully prepared rather uniform drug nanoparticles (~100 nm in 
diameter). These nanoparticles were amorphous and show an improved dissolution profile compared 
with untreated drug powders.  NME could be used as a general method to produce nanoparticles of 
hydrophobic drugs. 
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Parmar71 et al., (2011) designed Valsartan nanoparticles is an antihypertensive drug with 
poor oral bioavailability range from 10-35% because poor solubility dissolution and most 
importantly extensive first pass hepatic metabolism.The present study deals with the development 
and characterization of valsartan loaded solid lipid nanoparticles to enhance the solubility by pass 
hepatic metabolism and enhance the lymphatic absorption leading to improved bioavailability.  
 
 
Vaibhav Shukla72 et al., (2012) developed Dilitiazem Hcl nanoparticles it is an  
antihypertensive agent that antagonizes the action of beta 1- Receptor, DTZ when gives orally is well 
absorbed from the gastro intestinal tract and is subjected to an extensive first pass effect. DTZ 
undergoes extensive metabolism in which only 2% to 4% of the unchanged drug appear in the urine. 
Drug which induce or inhibit hepatic microsomal enzymes may alte DTZ disposition. It has been 
reported that the absolute bioavailability of DTZ when the given orally is 30-40% the biological half 
life of DTZ is 4-6 hrs and the main site of absorption is proximal small intenstine. A muco adhesive  
nanoparticles delivery system was envisioned for DTZ as such a system when administered would 
adhere on the gastric mucosa for a prolong period of time and the drug would be available at the 
main site of absorption. 
 
 
Madhushri73 et al., (2012) formulated solid lipid nanoparticles containing Clotrimazole for 
treatment of fungal infections like eczema, itching, pruritis etc. Topical formulation enriched with 
SLN of Clotrimazole was prepared. The solid lipid nanoparticulate dispersion of Clotrimazole was 
prepared by hot homogenization technique using polymers like Carbopol 934, mannitol and PEG 
6000. The nanoparticulate dispersion was evaluated for various parameters such as physical 
evaluations, particle size, diffusion studies, DSC, SEM, stability studies. The solid lipid 
nanoparticulate dispersion showed mean particle size less than 1000 nm. Differential scanning 
Calorimetry studies revealed no drug excipient compatibility. Diffusion studies release profile of 
clotrimazole from nanoparticulate dispersion showed prolonged drug release and all other 
evaluations were found to be complied the limits. formulation of SLN containing clotrimazole can be 
successfully formulated to localize the drug in the skin for to treat topical fungal infections. 
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Mohammed Khan74 et al., (2012) developed and evaluated mucoadhesive nanoparticles of 
chitosan using Tramadol Hcl. Spray drying method was employed for producing nanoparticles using 
different drug to polymer ratio. Nanoparticles were evaluated for variables like yield, drug loading, 
entrapment efficiency, swelling, invitro mucoadhesion, particle size, polydispersity index & zeta 
potential, scanning electron microscopy, transmission electron microscopy, X-ray diffraction study 
and drug polymer compatibility by differential scanning calorimetry & Fourier Transform Infrared 
Radiation studies. Tramadol HCl loaded chitosan nanoparticles is a promising delivery through nasal 
route for relief of pain. 
 
 
  Arjun Dedakia75 et al., (2013) prepared Poly caprolactone composite microparticles by 
w/o/w emulsion method. The drug as Theophylline from Xanthine derivative is still widely used as 
an effective bronchodilator in the disease of Asthma .Theophylline is used as a prophylactic drug and 
to prevent acute exacerbations of asthma also. The drug release in different dosage forms and find 
out the different burst effect in different dosage forms. The different batches of different dosage 
forms like drug containing microparticles, blank microparticles, and drug containing nano particles, 
blank nanoparticles, blank Composite Microparticles and drug containing the composite 
microparticles. Furthermore Double Emulsion Solvent Evaporation Method(W1/O/W2) was used to 
prepare these all type of dosage forms. The prepared Polycaprolactone composite microparticles was 
characterized by % Yield ,Particle size analysis, Zeta Potential, drug loading efficiency, X ray 
diffraction study and scanning Electron Microscopy. The different types of ratio of polymers to drugs 
are used. 
  
 
 
Srinivas76 et al., (2012) formulated of Moxifloxacin hydrochloride ocular nanoparticles. The 
nanoparticles were prepared by solvent displacement method using Eudragit RL 100 as a polymer. 
Different formulations were prepared by varying the ratios of drug and polymer and varying the 
ratios of organic and aqueous phase. The formulations were evaluated in terms of particle size, FTIR, 
drug entrapment efficiency and invitro drug release profile was examined. The antibacterial activity 
against gram positive and gram negative bacteria were determined. Invivo studies were carried out by 
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Draize test. The mean particle size for drug loaded formulations was found to be below 200 nm. The 
formulation possesses good antibiotic activity against Escherichia coli, Bacillus subtilus and 
Staphylococcus aureus microorganism and no eye irritation on invivo testing.  
 
 
Jun Sung Kim77 et al., (2007) developed the antimicrobial effects of silver (Ag) ion or salts 
are well known, Stable Ag nanoparticles were prepared and their shape and size distribution 
characterized by particle characterizer and transmission electron microscopic study. The 
antimicrobial activity of Ag nanoparticles was investigated against yeast, Escherichia coli, and 
Staphylococcus aureus. In these tests, Muller Hinton agar plates were used and Ag results, yeast and 
E. coli were inhibited at the low concentration of Ag nanoparticles, whereas the growth-inhibitory 
effects on S. aureus were mild. The free-radical generation effect of Ag nanoparticles on microbial 
growth inhibition was investigated by electron spin resonance spectroscopy. Ag nanoparticles can be 
used as effective growth inhibitors in various microorganisms, making them applicable to diverse 
medical devices and antimicrobial control systems. 
 
 
Dastagiri78 et al., (2013) prepared antineoplastic drug loaded polymeric nanoparticles using 
biodegradable polymers (Chitosan and Eudragit RS 100) by emulsion droplet coalescence method. 
The model drug used here is 5-fluorouracil which is a pyrimidine analogue that is mainly used to 
treat colonic carcinoma, under the category of anti-neoplastic drugs. Tween 20 was used as 
emulsifier and colloidal stabilizer. The prepared nanoparticles were evaluated for particle size, 
surface morphology by TEM, surface charge, drug loading and entrapment efficiency, and for drug 
release by diffusion. Results show that the prepared nanoparticles are in nanosize, below 1000 nm, 
having appropriate zeta potential values with better entrapment of drug and controlled release of drug 
for a period of 12 hrs. with high entrapment efficiency, optimum zeta potential, and showing more 
controlled release of drug.    
 
 
 Rajkumari79 et al., (2011) prepared the oral mucoadhesive sustained release nanoparticles 
of Clarithromycin in order to improve its therapeutic effect and reducing dosing frequency and its 
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dose related side effects. Clarithromycin containing chitosan nanoparticles were prepared by 
ionotropic gelation method. The method is reproducible easy and led to the efficient entrapment. 
Formulation had spherical particles in the particle range from 100 - 1500nm. Some process variables 
like effect of chitosan concentration, TPP concentration, acetic acid concentration were also 
evaluated with respect to drug content and encapsulation efficiency. The maximum encapsulation 
efficiency and drug content were 67.43 % and 6.13. The sustained release behavior of chitosan 
nanoparticles were evaluated both in phosphate buffer saline and simulated gastric fluid and results 
revealed that clarithromycin loaded chitosan nanoparticles are most suitable mode of delivery of drug 
for promising therapeutic action. 
 
 
Umasankar80 et al., (2010) formulated of Cytarabine nanoparticles. Cytarabine is a synthetic 
pyrimidine nucleoside. Cytarabine is most commonly used to treat acute myeloid leukaemia. 
minimize the frequency of doses and toxicity and to improve the therapeutic efficacy by formulating 
cytarabine nanoparticle. Cytarabine nanoparticles were formulating by ionic gelation method using 
polymer chitosan with three different ratios. Nanparticles were characterized by determining its 
particle size, drug entrapment efficiency, drug release and stability studies. The particle size ranged 
between 350nm to 600nm. Drug content was found to be supportive to the drug release pattern. The 
invitro release of cytarabine nanoparticles were carried out which exhibited a sustained release of 
cytarabine from nanoparticles up to 16 hrs. The results showed that nanoparticles were more 
beneficial in providing drug delivery system 
 
Vimal Kumar Varma81 et al., (2009) prepared Diclofenac Sodium loaded ethyl cellulose 
composite magnetic microspheres. Diclofenac sodium-containing ethyl cellulose micro particles 
were prepared by the Emulsion-solvent evaporation method with a view for use in the application of 
magnetic carrier technology. The properties of these magnetic microspheres, such as morphological, 
magnetic susceptibility and polymer-drug interactions were characterized by different techniques 
.The loading efficiency and swelling kinetics magnetic microspheres were also studied. The 
formulated microspheres were below 5μm and spherical in nature as evidenced from SEM. The 
invitro release profile was studied in normal saline medium up to 7 hrs using USP XXII dissolution 
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apparatus. Drug release in the first hour was found to increase and reached a maximum, releasing 
approximately 57.46% to 81.44% of the total drug content from the microspheres within 7 hrs. A 
third order equation for the drug release was also calculated. Microspheres showed greater retention 
time under the influence of magnetic field created by an electromagnet with field strength 8000 G, 
when compared to the retention in the absence of magnetic field. Magnetic ethyl cellulose 
microspheres could be retained at their target site invivo,following the application of the magnetic 
field and are being capable of releasing the drug for an extended period of time, thus making them a 
suitable depot for delivering chemotherapeutic agent invivo. 
 
 
Thiagarajan Madheswaran82 et al., (2013) designed of Finasteride-Loaded Liquid 
crystalline nanoparticles for topical delivery liquid crystalline nanoparticles in the treatment of 
androgenetic alopecia. The potential of this nanocarrier, FNS-loaded LCN was prepared by 
ultrasonication method and characterized for size, shape, invitro release, and skin permeation 
retention properties. The particle size ranged from 153.8 to 170.2 nm with a cubical shape and 
exhibited controlled release profile with less than 20% of the drug released in the first 24 hrs. The 
release profile was significantly altered with addition of different additives. Formulation with lower 
monolein exhibited higher skin permeation with a flux rate of 0.0610.005 μg cm 24 hrs. The 
permeation however, significantly increased with glycerol, propylene glycol, and polyethylene glycol 
400, while it declined for the addition of oleic acid. 
 
 
Azza A Hasan83 et al., (2012) prepared anti-glucomatous Dorzolamide hydrochloride-
(Dorzo) loaded nanoparticles as a controlled release system. Eudragit RS 100 (RS) and/or RL 100 
(RL) were used in formulations by an opportunely adapted Quasi-emulsion solvent diffusion 
technique. The formulations were evaluated in terms of particle size, zeta potential, drug entrapment, 
and release profile. All formulations showed tiny particle size varying from 114 to 395 nm for RS 
and 65 to 277 nm for RL. Positive zeta potential was 19 to 32 mV for RS and 23 to 42 mV for RL 
formulations. Increasing  polymer concentration lead to increase the percentage of drug entrapped in 
all batches, to a certain extent (drug: polymer 1:4). Nanoparticles prepared using RL showed lower 
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entrapment efficiency than RS. In contrast, increasing the stirring rate resulted in an increase in the 
percentage of Dorzo entrapped. A prolonged drug release was shown by all the formulations. 
Increasing the polymer concentration caused a decrease in the release rate. Dorzo-loaded 
nanoparticles could represent promising drug ophthalmic carriers, due to small particle size, positive 
zeta potential, and sustained release profile. 
 
 
             Beny Baby84 et al., (2012) prepared nanoparticles of Levofloxacin by ionic gelation method 
using chitosan as a biodegradable polymer and tripolyphosphate as the cross linking agent. The 
particle size of the prepared formulations varied between 190 and 632 nm. The nanoparticles showed 
favorable drug entrapment efficiency which varied between 60.06 ± 0.06 % and 74.29 ± 0.04 % and 
the drug content ranged between 67.20 ± 0.30 % and 76.10 ± 0.61 %. The FTIR spectral studies and 
DSC thermogram indicated that there was no interaction between the drug and polymers used. The 
scanning electron microscopy indicated that prepared nanoparticles were discrete, uniform and 
spherical with a smooth surface. According to this model, the drug releases from these formulations 
may be controlled by diffusion through the micropores. During and at the end of the stability study, 
the tested formulation showed non-significantly different drug content, entrapment efficiency and 
invitro drug release from that observed at the beginning of the study. No color changes were also 
observed during the study period. 
 
 
                     Ahmed Abushrida85 et al., (2011) investigated with the potential for long circulation 
times or the ability to preferentially reach particular tissues. The preparation of iron oxide 
nanoparticles was achieved using inorganic solution methods to prepare particles of small size using 
a narrow size distribution. The nanoparticles were coated with dextran and carboxymethyl dextran as 
reference materials using the same method as in the preparation of the iron oxide nanoparticles. the 
biodegradable polymer poly(glycerol adipate) (PGA) as a coating for iron oxide nanoparticles. PGA 
is already used in drug delivery systems and showed an ability to control the rate of release of the 
drug. 
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Khemariya86 et al., (2010)  prepared solid lipid nanoparticles for Nateglinide method and 
characterization-Solid lipid nanoparticles (SLNPs) based on different lipidic components have been 
produced by modified solvent injection method and characterized for Nateglinide encapsulation 
efficiency, morphology, zeta potential, particle size, and drug release. Morphology and dimensional 
distribution have been investigated by electron microscopy and Photon Correlation Spectroscopy. 
Cell viability experiments demonstrate that SLNPs exhibit no toxicity. Spherical SLNPs with an 
average particle size of ~173 nm were formulated. Delivery of Nateglinide by SLNPs led to a 
significantly higher accumulation by the endothelial cell monolayer as compared to the drug in 
aqueous solution. invitro release kinetics based on a dialysis method demonstrated that Nateglinide 
was released in a prolonged fashion for 24 hrs. Both free and encapsulated drug reduced the time 
spent on the blocks in the bar test, although the action of encapsulated  Nateglinide was more rapid in 
onset and prolonged than free drug. SLNPs would be promising drug delivery carriers to enhance 
delivery of Nateglinide. 
 
 
Nagavarma87 et al.,(2010) prepared Polymeric nanoparticles (PNPs) defined as particulate 
dispersions or solid particles with size in the range of 10-1000nm. There has been a considerable 
research interest in the area of drug delivery using particulate delivery systems as carriers for small 
and large molecules. Particulate systems like nanoparticles have been used as a physical approach to 
alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug 
molecules. Polymeric nanoparticles have been extensively studied as particulate carriers in the 
pharmaceutical and medical fields, because they show promise as drug delivery systems as a result of 
their controlled and sustained release properties, subcellular size, biocompatibility with tissue and 
cells.  
 
               G. Nabiyouni 88 et al.,   (2011)    investigated   the   surface   adsorption   of    PEG   and  
polyvinyl alcohol (PVA) with different molecular weights onto the Zinc oxide (ZnO) nanoparticles 
The  ZnO   nanoparticles   are  then  analyzed   using  Fourier  transform  infra  red  (FTIR),  X-ray  
diffraction (XRD) and  thermogravimetric  analysis   (TGA) techniques. The  aggregation  of   nano  
particles    before    and   after  polymer  adsorption    is   also  investigated   by  scanning  electron 
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microscopy  (SEM).   Adsorbing   the  PEG   and  PVA,   due  to  a   relatively   large   electrostatic  
repulsive   force  between   ZnO  nano  particles,   the  size of  aggregated   nanoparticles  decreases.   
The low  molecular  weight  polymers exhibit a higher adsorption rate  on the particles’ surfaces in
comparison to the polymers with high molecular weight. 
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3.0 RESEARCH ENVISAGED 
3.1 AIM OF WORK 
 
Development of nanoparticles are one of the emerging fields of nanotechnology with 
several potential application in drug delivery, clinical medicine and research as well as in other 
discipline. The use of nanoparticles as drug carrier system is a very attractive controlled drug 
release. 
 
            Irbesartan is an angiotensin receptor blockers used mainly for the treatment of 
hypertension. It belongs to class Π drug according to biopharmaceutical classification system.  
 
The bioavailability of the valsartan after oral administration is low (60%) with higher 
variability. The present study was aimed at developing nanoparticle of irbesartan in order to 
improve the bioavailability and efficacy in treatment of hypertension. 
 
            Irbesartan is a poorly water soluble drug. To increase solubility of the drug and reduce 
the dose frequency and improve the bioavailability the study was aimed at nanoparticle of 
Irbesartan. 
 
     Thus the present work is to Develop and characterize a nanoparticulate drug delivery 
system of antihypertensive drug (Irbesartan) and also 
 
 To increase the solubility 
 To overcome variable systemic availability. 
 To overcome side effect. 
 To overcome the drug resistance on long term. 
 Specific site drug delivery at controlled rate. 
 Prolonged systemic circulation. 
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                                             3.2. PLAN AND   SCOPE OF WORK 
 
Plan of the present work involves the following; 
 
1. Preformulation studies involve observation of physical and chemical data   
available. The  identification  of  raw  materials   and   compatibility  studies  
between  drug  and polymer is to  be  done  by  using   Infrared  spectrophotometry. 
 
2. Preparation of  Irbesatran  Nanoparticles  prepared  by  Precipitation  Method. 
 
3. Formulation of   Irbesartan Nanoparticles in various ratios of drug and polymer. 
 
4. The best formulation will be selected based on the results of following    
parameters. The prepared  nanoparticles is to be evaluated by  following   chemical     
characteristics 
 Drug entrapment efficiency. 
 In vitro drug release of formulated nanoparticles. 
 
5. Surface morphology of formulation (SEM) of the optimized formulation. 
 
6. Zeta potential analysis of the optimized formulation. 
 
7. Stability studies for the best formulation at different temperature. 
 
8. Drug release kinetics. 
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4. METHODOLOGY 
 
4.1. INSTRUMENTS AND MATERIALS USED 
 
 TABLE.NO.1 MATERIALS USED 
 
 
 
 
 
 
 
 
 
 
 
 
 
     MATERIALS      SOURCE 
Irbesartan Hetero Laboratory Ltd.(Chennai) 
Poly vinyl alcohol Micro labs, Hosur.(Karnataka) 
β cyclodextrine Micro labs, Hosur.(Karnataka) 
Potassium dihydrogen phosphate S.D.Finechemicals, Boisar.(Maharashtra) 
Disodium hydrogen phosphate S.D.Finechemicals, Boisar.(Maharashtra) 
Sodium Hydroxide S.D.Finechemicals, Boisar.(Maharashtra) 
Ethanol S.D.Finechemicals, Boisar.(Maharashtra) 
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 TABLE.NO.2 INSTRUMENTS USED 
 
 
EQUIPMENTS 
 
SOURCE 
Vortex mixer Remi motors Ltd, Mumbai.(SC-1275) 
Electronic balance Shimadzu Corporation, Japan.(ELB300) 
Stability chamber Osworld, Mumbai.(F-2749) 
Ultra centrifuge Remi motors Ltd, Mumbai.(L-3452) 
pH – meter ElicoPvtLtd, Chennai.(SC-1352) 
FTIR spectroscopy Perkin Elmer, Germany.(D-7864) 
Double beam UV spectrophotometer Perkin Elmer, Germany(S-8965) 
Hot air oven Biochemicals, Mumbai.(S-501) 
Membrane filter Gotting Ltd, Germany.(G-678) 
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4.2. DRUG PROFILE89 
IRBESARTAN 
Chemical structure 
 
 
Molecular formula :  C22H28N6O 
 
Molecular weight   :  428.53 
Chemical Name      : 2-butyl-3-[P-(0-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazapiro[4,4]non- 
    1-en-4-one.  
Solubility       : irbesartan is insoluble in water,slightly soluble in alcohol and   
      dicholoromethane.  
  
 
        
 
 
Pharmacology:  
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic 
hypertension and left ventricular hypertrophy. May be used as a first line agent to delay 
progression of diabetic nephropathy. Losartan may be also used as a second line agent in the 
treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary 
artery disease in those intolerant of ACE inhibitors. 
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Pharmacodynamics: 
                  Angiotensin II, the principal pressor agent of the renin-angiotensin system, is 
responsible for effects such as vasoconstriction, stimulation of synthesis and release of 
aldosterone, cardiac stimulation, and renal reabsorption of sodium. Irbesartan is a specific 
competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for 
the AT1 receptor than for the AT2 receptor and no agonist activity. Irbesartan's inhibition of 
angiotensin II binding to the AT1 receptor leads to multiple effects including vasodilation, a 
reduction in the secretion of vasopressin, and reduction in the production and secretion of 
aldosterone. The resulting effect is a decrease in blood pressure  
Mechanism of action  
          Irbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that 
selectively blocks the binding of angiotensin II to the AT1 receptor. In the renin-angiotensin 
system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin 
II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which 
decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also 
acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of 
angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of 
aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also 
inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin 
II plasma concentrations do not counteract the blood pressure–lowering effect that occurs. The 
action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to 
angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the 
hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other 
ARBs do not interfere with response to bradykinins and substance P, which allows for the 
absence of adverse effects that are present in ACE inhibitors.  
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Pharmacokinetics: 
Absorption 
 Rapid and complete with an average absolute bioavailability of 60-80%. Food has no 
affect on bioavailability. 
Distribution 
 53- 93 L. 90% bound to serum proteins. 
Metabolism  
 Hepatic Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro 
studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was 
oxidized primarily by 2C9; metabolism by 3A4 was negligible. 
Elimination 
 Half-life is about 11-15 hrs. Irbesartan is metabolized via glucuronide conjugation and 
oxidation. Irbesartan and its metabolites are excreted by both biliary and renal routes. Irbesartan 
is excreted in the milk of lactating rats.clearence value 157-176 mL/min. 
Side effects 
 Most commonly, headache and dizziness 
 Chills 
 Cold sweats 
 confusion 
Dosage and Administration 
Hypertension 
Adults  
 Initial dosage: 150 mg once daily. 
 Maximum dosage: 300 mg once daily. 
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Diabetic Nephropathy 
Adult 
Dose:  300mg daily treatment of diabetic nephropathy with an elevated serum creatinine and 
proteinuria in patient with type2 diabetes and hypertension 
 Renal dose adjustments - No adjustments 
 Liver dose adjustments - No adjustments 
Storage/Stability 
 Store at 59°to86°F in tightly closed container. Protect from moisture. 
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4.3. POLYMER PROFILE 
POLY VINYL ALCOHOL 
Synonym 
          Poly ethanol, homo polymer, Polyviol, Vinol, Alvyl, Alcotex.  
 Empirical formula 
       (C2H4O)X 
Molecular Weigh 
              13000-23000  
Structural formula:                                                       
                                                         
Application  
 Paper adhesive with boric acid in spiral tube winding and solid board production 
 Thickener, modifier, in polyvinyl acetate glues 
 Textile sizing agent 
 Paper coatings, release liner 
 As a water-soluble film useful for packaging. An example is the envelope containing 
laundry detergent in "liqui-tabs". 
 Feminine hygiene and adult incontinence products as a biodegradable plastic backing 
sheet. 
 Carbon dioxide barrier in polyethylene terephthalate (PET) bottles 
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Typical properties 
   Melting Point      :   200 °C  
   Boiling Point       :   228 °C (Predicted) 
   Density                :     1.19-1.31 g/cm3 
Solubility 
             Soluble in water  
Stability and Storage 
           Store at room temperature 
 
β  -CYCLODEXTRIN 
Synonym 
          Cycloheptaamylose, Cyclomaltoheptaose; Betadex  
Empirical formula 
       C42H70O35 
Molecular Weight 
              1134.98 
Description 
             β-Cyclodextrin is made of homogeneous cyclic α1,4-linked D-glucopyranose units in a 
seven member ring. Forms clathrates and suitable for use with dansyl chloride to form water-
soluble complexes for fluorescent labeling of proteins. 
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Structural formula 
 
 
 
Application 
            Useful for forming water-soluble complexes for fluorescent labeling of proteins 
Typical properties 
   Melting Point      :   290-300 °C (lit.)(dec.) 
   Boiling Point       :   1541.18 °C at 760 mmHg (Predicted) 
   Density                :     1.44 g/cm3 at 20 
Solubility 
             Soluble in water (10 mg/ml), and 1 M NH4OH (50 mg/ml) 
Stability and Storage 
           Store at room temperature 
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5. EXPERIMENTAL INVESTIGATIONS 
 
5.1 CONSTRUCTION OF STANDARD CURVE FOR IRBESARTAN 
 UV Spectroscopy Method 
      Irbesartan is estimated spectrophotometrically at 220 nm and it obey Beer-Lambert` s Law in 
the range of 5-50 mcg /ml. 
 
Detrminatiion of Absorbance maximum (ƛmax) 
Irbesartan was dissolved in phosphate buffer saline pH 7.4 Solution with 50 µg/ml 
concentration was prepared by suitable dilution. The solution was scanned in UV 
spectrophotometer at 200 to 400 nm using phosphate buffer saline pH 7.4 as blank. Absorbance 
maximum was determined as 220 nm. The drug was later quantified by measuring the 
absorbance at 220 nm in phosphate buffer saline pH 7.4  
 
Preparation of release media 
 1.38gm of disodium hydrogen phosphate, 0.19gm of potassium dihydrogen phosphate 
and 8gm of sodium chloride was dissolved in sufficient amount of distilled water and produced 
1000ml. pH was adjusted to 7.4 
 
4.5.2. Standard curve for Irbesartan (By UV method) 90  
A stock solution of Irbesartan was prepared by dissolving 50mg of pure drug in pH 7.4 
phosphate buffer saline in a 100ml volumetric flask. From the above stock solution, 10ml of 
solution was pipetted out into a 100ml volumetric flask and made upto the mark. From the 
secondary stock solution, 1ml, 2ml, 3ml, 4ml upto 10ml were taken and diluted to 10ml to obtain 
the concentrationof 5 to 50 μg/ml.The absorbance of the solutions were measured against the 
blank in a UV spectrophotometer. A calibration curve was obtained at 220 nm for a series of 
concentration in the range of 5 to 50 μg/ml. 
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TABLE.3 CALIBRATION CURVE OF IRBESARTAN 
 
Concentration  
(µg/ml) 
Absorbance at 220nm 
5           0.097 
10           0.197 
15           0.298 
20           0.381 
25           0.494 
30           0.587 
35           0.678 
40           0.781 
45           0.877 
50           0.966 
 
 
 Fig: 1 STANDARD CURVE FOR IRBESARTAN  
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5.2. PREFORMULATION STUDY 
IR studies: 
 Identification of the pure drug was performed using IR spectroscopy. IR spectroscopy 
(using Perkin Elmer) by KBr pellet method carried out on drug. They are compressed under 15 
tones pressure in a hydraulic press to form a transparent pellet. The pellet was scanned from 
4000-400cm-1 in a spectrophometer and peaks obtained were identified. 
 
  
5.3. METHOD OF PREPARATION OF IRBESARTAN NANOPARTICLE 
       NANOPRECIPITATION METHOD: 
 All batches of nanoparticles were prepared by nanoprecipitation method. The required 
quantity of polymer dissolved in 3ml ethanol, and drug was dissolved in 3ml of ethanol,  added 
finally both were mixed together and added β-cyclodextrin. The mixer was homogenized in 
vortex mixture for 1 min and then the Final volume of the preparation was to 10ml. Then this 
preparation was centrifuged at 15000rpm at 40c for half an hour. The supernatant was discarded 
and precipitate was washed 3times with distilled water. The nanoparticles thus obtained were 
dried overnight in oven at 600c and stored in desiccators. 
  The prepared formulation were characterized for loading efficiency, entrapment 
efficiency, particle size, particle size distribution , zeta potential and drug polymer compatability 
studies. 
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                    Table: 6 Various Composition of Nanoparticles Formulation 
 
 
 
 
 
 
 
 
      
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FORMULATION 
CODE 
DRUG 
(Irbesartan) 
in mg 
PAV 
 
in mg 
β 
CYCLODEXTRIN 
 
F1 50 25 5  
F2 50 50 5 
F3 50 75 5 
F4 50 100 5 
F5 50 25 10 
F6 50 50 10 
F7 50 75 10 
F8 50 100 10 
F9 50 25 15 
F10 50 50 15 
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5.4 .EVALUATIONOF NANOPARTICLES 
 
 DRUG ENTRAPMENT STUDY 
The entrapment efficiency study was determined by free drug content in the supernatant 
which is obtained after centrifuging the solid lipid suspension at ( 15,000rpm for 20 min at zero 
using ultra centrifuge ) The absorbance was measured at 220 nm by UV spectrophotometrically.  
INVITRO DRUG RELESE STUDIES 
BY UV Spectrophotometric Method: 
        The invitro drug release study was carried out by using the diffusion membrane technique. 
The nanoparticles preparation was placed in a dialysis membrane and it is dropped in a beaker 
containing 200ml of diffusion medium (phosphate buffer saline pH 7.4) the medium was 
maintained at 37o C under magnetic stirred at constant speed. At fixed time interval of 1ml 
sample was taken from the diffusion medium for every 1 hrs and it was replaced by 1 ml fresh 
medium. This process was carried out for 24 hrs. The sample was measured UV 
spectrometrically at 220nm. The percentage of drug released at various time intervals was 
calculated from calibration graph. 
 
SCANNING ELECTRON MICROSCOPY 
The optimized formulation was morphologically characterized by scanning electron 
microscopy (SEM).The sample for SEM analysis was mounted in the specimen by using an 
adhesive, small sample which was mounted directly in scotsch double adhesive tape. The sample 
was analyzed in scanning electron microscope operated at 15 kv and image was taken. 
 
SURFACE CHARGE (ZETA POTENTIAL DETERMINATION) 
Zeta potential is an important parameter to evaluate and establish an optimum condition 
for stability of colloidal or dispersed systems .The prepared nanoparticle suspension were 
characterized with respect to zeta potential by using zeta potential analyser (Malvern Zeta 
seizer). Zeta potential is electrical charges on particles surface it create electrical barrier it is very 
important for drug stability. The effect of polyvinyl alcohol and β-cyclodextrine on the surface 
characteristics of the nanoparticle was studied. 
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pH AND PHYSICAL APPERANCE: 
The pH of the formulation was measured using pH meter. It plays a vital role in process 
of stability and formulation activity.The physical appearance of the formulation such as colour 
and suspended foreign particulate matter were to be examined. 
 
STABILITY STUDIES OF NANOPARTICLES 
 The Stability studies of nanoparticles involves observing the formulation at 45oC /70% 
RH which constitutes accelerated condition and (4oC) on refrigerator and room temperature. The 
formulations were kept in both the temperature for 3 months and sufficient amount of sample 
were taken at periodic intervals, for performing the following tests. 
                                                a. Physical appearance 
                                                b. pH of the solution 
                                                c. In vitro drug release (Dissolution) 
                                               d. Percentage of drug entrapment 
 
DRUG RELEASE KINETICS STUDIES 
The optimized formulation was subjected to graphical treatment to assess the kinetics of drug 
release 
 
ZERO ORDER PLOT 
 The zero order plot obtained by plotting cumulative % drug release versus time. 
 
HIGUCHI PLOT    
The Higuchi plot was made by plotting cumulative percentage (%) drug release versus Square 
root of time. 
 
KORESMEYER PLOT   
 The graph was obtained by log cumulative percenetage(%)  drug release versus log time. 
 
FIRST ORDER KINETIC RELEASE STUDY  
The first order plots were obtained by plotting log remaining cumulative percentage drug release 
versus time. 
RESULTS AND DISCUSSION 
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   RESULTS AND DISCUSSION 
 
DEVELOPMENT OF IRBESARTAN NANOPARTICLES37, 44 
 All batches of nanoparticles were prepared by nanoprecipitation method. The required 
quantity of polymer dissolved in 3ml ethanol, and drug was dissolved in 3ml of ethanol,  
added finally both were mixed together and added β-cyclodextrin. The mixer was 
homogenized in vortex mixture for 1 min and then the Final volume of the preparation was to 
10ml. Then this preparation was centrifuged at 15000rpm at 40C for half an hour. The 
supernatant was discarded and precipitate was washed 3 times with distilled water. The 
nanoparticles thus obtained were dried overnight in oven at 600C and stored in desiccators. 
  
Formulations with different ratios of polymer were prepared, several physiochemical 
characteristics of nanoparticles such as particle size determination, drug release profile, were 
investigated and stability of optimized formulation at various temperature was evaluated. 
 
 DRUG AND POLYMER COMPATABILITY STUDIES BY FTIR27, 76 
 Identification of the pure drug was performed using IR spectroscopy. IR spectroscopy 
(using Perkin Elmer) by KBr pellet method carried out on drug. They are compressed under 
15 tones pressure in a hydraulic press to form a transparent pellet. The pellet was scanned 
from 4000-400cm-1 in a spectrophometer and peaks obtained were identified. 
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TABLE 4: I.R SPECTRA DATA FOR PURE IRBESARTAN 
Wave no. (cm-1) Group   Assigned 
1730.21 
1408.06 
1099.46 
 
                   C=O   –   Stretching 
C=C   –   Stretching 
C-N   -   Stretching 
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TABLE 5: I.R SPCTERA DATA FOR PHYSICAL MIXTURE 
Wave no.(cm-1) Group   Assigned 
1734.01 
1409.06 
1099.43 
               C=O   –   Stretching 
C=C   –   Stretching 
C-N   -   Stretching 
 
REPORT: 
           In FTIR spectra the peaks of physical mixture was compared with the original spectra. 
Same peaks were observed, indicates no possible molecular interaction between the drug and 
the polymer. 
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ENTRAPMENT EFFICIENCY OF NANOPARTICLES31, 72 
         The entrapment efficiency of Irbesartan nanoparticles was prepared by nano 
precipitation method. The formulation F1(Irbesartan 50 mg with 25 mg of Polyvinyl alcohol 
and β -cyclodextrin ) shows less entrapment value of 60.16% this may be the due to repulsive 
force between drug and the polymer. 
         
 
                           Table No: 7 Entrapment efficiency of  Irbesartan nanoparticles 
 
 
Formulation  
code 
Drug 
(mg) 
Poly vinyl alohol 
(mg) 
β 
cyclodextrin 
(mg) 
Ethanol Entrapment 
Efficiency 
(%) 
F1 50 25 5 2% 60.16±0.14 
F2 50 50 5 2% 64.15±0.17 
F3 50 75 5 2% 68.28±0.15 
F4 50 100 5 2% 71.12±0.09 
F5 50 25 10 2% 88.23±0.12 
F6 50 50 10 2% 94.26±0.18 
F7 50 75 10 2% 99.38±0.08 
F8 50 100 10 2% 87.42±0.09 
F9 50 25 15 2% 85.35±0.06 
F10 50 50 15 2% 82.25±0.04 
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In formulation F2 Polymer concentration was increased (Irbesartan 50 mg with 50mg 
of Polyvinyl alcohol and 5 mg β -cyclodextrin ) the entrapment efficiency was to 64.15%. 
Further increase in polymer concentration in formulation F3 (Irbesartan 50 mg with 75 mg of 
Polyvinyl alcohol and 5mg β -cyclodextrin )entrapment efficiency was 68.28%. Further 
increase in polymer concentration in formulation F4 (Irbesartan 50 mg with 100 mg of 
Polyvinyl alcohol and5 mg β -cyclodextrin ) entrapment efficiency was 71.12%. Formulation 
F5, F6, was carried out by same process as like previous formulation but changes in polymer 
concentration 25mg, 50mg, 50 mg of Irbesartan and10 mg β -cyclodextrin was taken. The 
entrapment efficiency was found to be  F5,88.23% for F6,94 .26% . 
            Formulation F7 was carried out by increasing the polymer concentration same 
(Irbesartan 50 mg with 75 mg of Polyvinyl alcohol and 10 mg β -cyclodextrin ) the 
entrapment efficiency was increased to 99.38%. 
 
 Formulation F8 was carried out by increasing  the concentration (Irbesartan 50 mg 
with 100 mg of Polyvinyl alcohol and 10 mg β -cyclodextrin )  which give  the percentage of 
entrapment efficiency was 87.42% but In F8 the invitro  release of drug shows less than F7 
formulation. So F7 formulation is optimized and further study was carried out. 
 
   Further formulation F9 and F10 was carried out in same process, drug and polymer 
concentration (Irbesartan 50 mg with 25 and 50mg of Polyvinyl alcohol and 15 mg β -
cyclodextrin )  the Entrapment efficiency is F9 85.35%, F10 82.25% From the above result 
formulation F7 shows highest percentage of entrapment efficiency of 99.38%. So hence this 
formulation was optimized and further study was carried out.  
 In F1,F2,F3, F4 formulations, when increasing the polymer concentration the 
entrapment efficiency is not satisfactory limit. Nanoparticle using  5 mg β -cyclodextrin   
showed lower entrapment. 
      So further increasing the concentration of β –cyclodextrin in F5, F6 and F7 
formulations.  (Irbesartan 50 mg with 25 mg 50mg and 75 mg of Polyvinyl alcohol and 10 
mg β -cyclodextrin ). In this  formulations the entrapment efficiency was  F5 for 88.23% ,F6 
for 94.26% and F7 for 99.38%.In this the optimum entrapment efficiency obtained in F7. 
 
    Further increase the concentration of  β –cyclodextrin  in formulation F8,F9 and F10. 
The entrapment efficiency also decreased. 
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IN VITRO DRUG RELEASE PROFILE OF NANOPARTICLES 
 
 The in-vitro drug release of Irbesartan nanoparticles can be carried out by membrane             
  diffusion method for 24 hrs. 
 The  in-vitro drug release of Irbesartan  nanoparticles  with   Polyvinyl alcohol and  
       β –cyclodextrin. 
 The in-vitro drug release of formulation F1 (Irbesartan 50 mg with 25mg of 
Polyvinyl alcohol and 5 mg β -cyclodextrin )  The percentage of in vitro drug release 
was 97% in 9 hrs.     
 The formulation F2 was carried out by the increasing  the polymer concentration  
(Irbesartan 50 mg with 50mg of Polyvinyl alcohol and 5 mg β -cyclodextrin ) The 
percentage of  in vitro drug  release was found to be 96.40% in 11 hrs. 
  The formulation F3 was carried out by further increasing in polymer concentration 
   (Irbesartan 50 mg with 75 mg of Polyvinyl alcohol and 5 mg β -cyclodextrin )  The 
percentage of drug release was found to be 98.44% in 13 hrs.  
 The formulation F4 was carried out by further increasing in polymer concentration  
(Irbesartan 50 mg with 100mg of Polyvinyl alcohol and 5 mg β -cyclodextrin ). The 
percentage drug release found to be 96.2% in 16 hrs. 
 The formulation F5 was carried out by further increasing in polymer concentration 
(Irbesartan 50 mg with 25 mg of Polyvinyl alcohol and 10 mg β -cyclodextrin ). The 
percentage drug release was found to be 98.0% in 19 hrs. 
 The formulation F6 was carried out by further increased in polymer concentration 
(Irbesartan 50 mg with 50mg of Polyvinyl alcohol and 10 mg β -cyclodextrin ).The 
percentage drug release was found to be 94.42% in 24 hrs. 
 The formulation F7 was carried out by combination of (Irbesartan 50 mg with 75mg 
of Polyvinyl alcohol and 10 mg β -cyclodextrin ).  The percentage of drug release was 
found to be 98.46% in 24 hrs. 
 The formulation F8 was carried out by the combination of increasing the polymer 
concentration of (Irbesartan 50 mg with 100mg of Polyvinyl alcohol and 5 mg β -
cyclodextrin )  percentage drug release was found to be 88% in 24 hrs. 
 The formulation F9 was carried out by the combination of increased polymer 
concentration (Irbesartan 50 mg with 25 mg of Polyvinyl alcohol and 15 mg β -
cyclodextrin )  percentage of drug release was found to be 95% 14 hrs. 
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 The formulation F10 was carried out by the combination of increased polymer 
concentration  (Irbesartan 50 mg with 50mg of Polyvinyl alcohol and 15 mg β -
cyclodextrin )  percentage of drug release was found to be 96.4% 17 hrs. 
 From the above formulation (F1-F10) confirms that the percentage of drug release 
was satisfactory in formulation F7 and it shows higher percentage of drug release of 
98% for 24 hrs. So it was selected as a optimized formulation. 
 
When increasing  the polymer concentration the in vitro drug release also increased to 
a certain extent  in the drug and polymer ratio up to 1:1.5 
  
Further the polymer concentration is increased in F8  formulation the in vitro drug 
release increased but not extend upto 24hrs. So F7 was selected as a optimized formulation. 
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Table: 9.  In vitro drug release for formulation F-I 
  
Time(in Hrs) Cumulative  amount 
of drug release 
Cumulative % amount 
of drug release. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 
9.2 
12.4 
18.5 
22.3 
28.2 
34.1 
38.3 
42.5 
48.5 
 
18.41 
24.8 
37 
44.6 
56.4 
68.2 
76.6 
85 
97 
                  
 
                    INVITRO DRUG RELEASE FOR FORMULATION F-I 
 
Figure: 12 
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Table: 10. In vitro drug release for formulation F-II 
 
Time(in Hrs) Cumulative  amount 
of drug release 
Cumulative % amount 
of drug release. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
16 
19.08 
20.09 
23.10 
26.11 
33.13 
36.16 
40.18 
45.02 
47.2 
48.22 
32 
38.16 
40.18 
46.20 
52.22 
66.26 
72.33 
80.36 
90.04 
94.5 
96.40 
                   
INVITRO DRUG RELEASE FOR FORMULATION F-II 
 
Figure: 13 
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Table: 11.  In vitro drug release for formulation F-III 
        
Time         
(in Hrs) 
 
Cumulative 
Amount of drug release 
Cumulative % amount 
of drug release  
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
10.03 
13.05 
15.06 
18.07 
19.09 
23.09 
28.11 
29.14 
33.14 
36.16 
40.18 
44.2 
49.22 
 
20.6 
26.1 
30.12 
36.14 
38.18 
46.18 
56.22 
58.28 
66.28 
72.32 
80.36 
88.4 
98.44 
                                           
INVITRO DRUG RELEASE FOR FORMULATION –F-III 
Figure: 14 
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Table: 12. In vitro drug release for formulation F-IV 
Time             
(in Hrs) 
Cumulative  amount 
of drug release 
Cumulative % amount 
of drug release. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
 
7.2 
8.5 
11.2 
15.5 
16.8 
17.2 
19.8 
21.3 
27.2 
30.6 
33.5 
36.4 
38.2 
41.3 
44.5 
48.1 
 
14.4 
17.0 
22.4 
31.0 
33.6 
34.4 
39.6 
42.6 
54.4 
61.2 
67.0 
72.8 
76.4 
82.6 
89.0 
96.2 
 
INVITRO DRUG RELEASE FOR FORMULATION F-IV 
 
Figure: 15 
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Table.13. In vitro drug release for formulation F-V 
          
Time             
(in Hrs) 
Cumulative  amount 
of drug release 
Cumulative % amount of 
drug release. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
 
9 
10.04 
12.05 
14.06 
17.07 
18.08 
20.09 
22.10 
25.11 
26.12 
28.13 
31.14 
32.15 
34.16 
37.17 
40.18 
44.19 
47.20 
49.0 
 
18 
20.08 
24.10 
28.12 
34.14 
36.16 
40.20 
44.22 
50.25 
52.26 
56.26 
62.28 
64.32 
68.32 
74.36 
80.36 
88.38 
94.40 
98.0 
 
INVITRO DRUG RELEASE FOR FORMULATION F-V 
Figure: 16 
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Table: 14. In vitro drug release for formulation F-VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INVITRO DRUG RELEASE FOR FORMULATION –F-VI 
Figure-17 
 
Time            
(in Hrs) 
Cumulative amount of 
drug release 
Cumulative %amount 
of drug release 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
4.8 
5.7 
7.2 
8.8 
10.2 
11.6 
13.4 
14.8 
16.3 
17.9 
19.4 
21.2 
23.4 
25.2 
26.8 
29.2 
32.1 
34.4 
36.6 
38.9 
42.1 
44.5 
46.22 
47.21 
8.16 
10.14 
14.4 
17.6 
20.4 
23.2 
26.8 
29.6 
32.6 
35.8 
38.8 
42.4 
46.8 
50.4 
53.6 
58.4 
64.2 
68.8 
73.2 
77.8 
84.2 
89 
92.44 
94.42 
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Table: 15. In vitro drug release for formulation F-VII              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INVITRO DRUG RELEASE FOR FORMULATION F-VII 
Figure: 18 
 
Time            
(in Hrs) 
Cumulative amount 
of drug release 
Cumulative %amount 
of drug release 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
2 
4.01 
6.02 
8.03 
10.04 
12.05 
14.06 
16.07 
18.08 
20.09 
22.1 
24.11 
26.12 
29.13 
31.14 
33.15 
35.16 
37.17 
39.18 
41.19 
43.20 
45.21 
47.22 
49.23 
4 
8.02 
12.04 
16.06 
20.08 
24.1 
28.12 
32.14 
36.16 
40.18 
44.2 
48.22 
52.4 
58.26 
62.29 
66.31 
70.33 
74.35 
78.37 
82.39 
86.41 
90.43 
94.45 
98.46 
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Table: 16. In vitro drug release for formulation F-VIII 
Time         
(in Hrs) 
Cumulative amount 
of drug release 
Cumulative %amount 
of drug release 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
8.9 
9.8 
12.0 
13.5 
15.9 
16.8 
18.4 
20.3 
22.2 
24.4 
25.2 
26.7 
28.1 
29.7 
31.0 
32.2 
33.5 
35.1 
36.6 
38.2 
39.4 
41.1 
42.5 
44 
17.08 
19.06 
24 
27 
31.8 
33.6 
36.8 
40.6 
44.4 
48.8 
50.4 
53.4 
56.2 
59.4 
62 
64.4 
67 
70.2 
73.2 
76.4 
78.8 
82.2 
85 
88 
INVITRO DRUG RELEASE FOR FORMULATION F-VIII 
Figure: 19 
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Table: 17.  In vitro drug release for formulation F-IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INVITRO DRUG RELEASE FOR FORMULATION F-IX 
Figure: 20 
 
 
Time            
(in Hrs) 
Cumulative amount 
of drug release 
Cumulative 
%amount of drug 
release 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
8.6 
11.2 
13.3 
15.8 
17.2 
21.1 
23.9 
27.3 
30.8 
34.2 
37.1 
41.8 
44.2 
47.5 
 
17.2 
22.4 
23.6 
31.6 
34.4 
42.2 
47.8 
54.6 
61.6 
68.4 
74.2 
83.6 
88.4 
95 
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Table: 18. In vitro drug release for formulation F-X 
 
Time(in Hrs) Cumulative amount 
of drug release 
Cumulative %amount 
of drug release 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
 
8.2 
9.5 
11.6 
14.7 
16.2 
17.8 
19.9 
22.4 
25.9 
28.8 
31.5 
33.9 
36.1 
39.8 
42.9 
44.8 
48.2 
 
16.4 
19 
23.2 
29.4 
32.4 
35.4 
39.8 
44.8 
51.8 
57.4 
63 
67.8 
72.2 
79.6 
85.8 
89.4 
96.4 
 
INVITRO DRUG RELEASE FOR FORMULATION F-X 
Figure: 21 
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COMPARITIVE INVITRO RELEASE STUDY OF IRBESARTAN NANOPARTICLE 
FORMULATIONS F1 TO F10 
Figure: 22 
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6.5. SCANNING ELECTRON MICROSCOPY 11, 26 
            The surface characteristics of optimized formulation (F7) particle size were studied by 
scanning electron microscope.SEM image of prepared nanoparticle formulation shows the 
coating of polymer mixture on drug particles. The appearance of nanoparticles in scanning 
electron microscope is in granule form, which indicates a thin and uniform coating over the 
drug. SEM image revealed that the Irbesartan nanoparticles were in nano size range,and 
smooth spherical in shape in this F7 Formulation.  
    
 
 
 
 
 
 
Fig .No:12 SEM IMAGE OF F7 
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6.6.SURFACE CHARGE (ZETA POTENTIAL)19,42,25 
    The zeta potential of a nanoparticles is commonly used to characterize the surface 
charges property of nanoparticles. It reflects the electrical potential of particles influenced by 
the composition of the particles band the medium in which it is dispersed. When 
nanoparticles formulations are administered through intravenous route they are easily 
identified and detected by the phagocytes. The particle size and the hydrophobicity surface of 
the nanoparticles determine the adsorption of blood components (proteins) called as opsonins. 
The opsonin in turn decides the fate of the nanoparticles. Binding of these opsonins on to the 
surface is known as Opsoniazation. Non modified nanoparticles were rapidly opsoniazed and 
gets easily eliminated from the body. Hence, to increased  minimize the opsoniazation and to 
prolong the circulation of nanoparticles invivo.   
 
   The zeta potential of the nanoparticle formulation with poly vinyl alcohol 
(formulation F7) particles which present in the formulation are de-aggregated and remain 
same and more stable in the substance and zeta potential (mV) is 38 mv and zeta Deviation 
(mV) is 9.16 and conductivity (mS/cm) is 0.899.So this polymer is more suitable for 
nanoparticles preparation and the result shows smooth surface character and efficient repelled 
action and it decreases the opsoniazation. 
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RESULTS AND DISCUSSION 
  
Dept of Pharmaceutics, K.M College of Pharmacy, Madurai. Page 85 
 
6.7. STABILITY STUDIES OF IRBESARTAN NANOPARTICLES75: 
 
 The stability studies of optimized nanoparticle formulation F7 was carried our for 3 
months. The test was performed in three conditions 4o C, Room temperature and 45oC/70% 
RH. At the time interval of one month the nanoparticle formulation were evaluated for 
entrapment efficiency. The stability of nanoparticles formulation was more stable in 
refrigerator (4oC) when compared to room temperature and at (45oC/70% RH) 
 
Table: 18 Stability studies for Irbesartan nanoparticle 
 
 
S.NO Storage Condition 
Test 
parameters 1
st
 month 2th month 3rd month 
1 4oC 
 
pH 
 
colour 
 
 
stability 
7.5 
 
Clear& 
colour less 
 
97.46 
7.5 
 
Clear& 
colour less 
 
96.47 
 
7.5 
 
Clear & 
colour less 
 
95.46 
2 Room 
Temperature 
pH 
 
colour 
 
 
stability 
 
7.4 
 
Clear & 
colour less 
 
    93.41 
7.4 
 
Clear & 
colour less 
 
92.42 
7.3 
 
Clear & 
colour less 
 
91.42 
3 Acceleration 
condition at  
45oC/70% 
RH 
pH  
 
Colour 
 
 
Stability   
 
7.4 
 
Clear & 
 
colourless 
90.42 
7.3 
 
Clear& 
 
colourless 
88.24 
7.3 
 
Clear& 
 
colourless 
86.41 
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Table: 19 In vitro release for optimized formulation (F7) stability study at 4oC 
Time( in Hrs) Cumulative % amount of drug release  
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
1st Month 
            4 
7.02 
11.03 
14.05 
19.07 
23.09 
26.11 
31.13 
35.15 
39.17 
43.18 
47.21 
52.23 
56.26 
61.28 
65.31 
69.32 
73.34 
78.36 
81.38 
85.40 
88.41 
93.45 
97.46 
2nd Month 
3 
7.03 
11.05 
14.07 
19.09 
22.09 
25.11 
30.13 
34.16 
38.18 
43.21 
46.22 
51.25 
55.27 
60.28 
64.31 
68.33 
72.36 
77.38 
80.41 
84.42 
88.44 
93.45 
96.47 
3rd Month 
3 
6.01 
10.03 
13.05 
18.07 
20.09 
24.11 
29.14 
34.17 
37.18 
41.20 
45.22 
50.25 
55.27 
58.29 
64.31 
67.33 
71.35 
77.36 
79.39 
83.41 
87.43 
92.44 
95.46 
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Fig.No.13: STABILITY STUDY RELEASE DATA FOR FORMULATION (F7) 
 AT 4OC 
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Table: 20 In vitro data for optimized formulation (F7) stability study at room 
temperature 
 
Time( in Hrs) Cumulative % amount of drug release  
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
1st Month 
3 
6.02 
10.04 
13.05 
17.06 
20.07 
23.09 
29.11 
34.13 
36.15 
41.17 
44.19 
50.21 
54.23 
58.25 
64.27 
67.29 
70.31 
76.33 
77.34 
82.35 
84.37 
88.38 
93.41 
2nd Month 
3 
6.02 
10.04 
12.05 
16.07 
19.10 
23.51 
28.32 
33.15 
36.17 
41.18 
44.20 
50.23 
54.24 
58.26 
64.28 
67.30 
70.32 
76.33 
77.86 
82.37 
85.37 
89.41 
92.42 
3rd Month 
3 
6.04 
11.55 
13.07 
15.1 
18.11 
22.63 
26.15 
32.17 
34.18 
38.20 
42.23 
46.24 
50.26 
53.28 
57.3 
63.82 
68.34 
72.86 
76.36 
81.37 
84.41 
87.24 
91.42 
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Fig.No.14: STABILITY STUDY RELEASE DATA FOR FORMULATION (F7)  
 AT ROOM TEMPERATURE 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
  
Dept of Pharmaceutics, K.M College of Pharmacy, Madurai. Page 90 
 
Table: 21 In vitro data for optimized formulation (F7) stability study at 45oc/75%RH 
 
Time( in Hrs) Cumulative % amount of drug release  
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
1st Month 
3 
6.04 
11.05 
13.07 
15.1 
18.11 
22.63 
26.15 
32.17 
34.18 
38.20 
42.23 
46.24 
50.26 
53.28 
57.3 
63.32 
68.34 
72.36 
76.36 
81.37 
84.41 
87.41 
90.42 
2nd Month 
3 
6.04 
10.05 
12.06 
13.07 
15.1 
17.11 
22.13 
25.15 
31.17 
34.18 
38.20 
42.23 
45.24 
49.26 
52.28 
56.3 
61.32 
66.34 
71.36 
75.36 
79.37 
84.41 
88.24 
3rd Month 
3 
6.04 
10.05 
11.06 
12.07 
14.1 
16.11 
21.13 
26.15 
30.17 
34.18 
37.20 
41.23 
44.24 
48.26 
53.28 
57.30 
62.82 
67.34 
71.86 
74.36 
78.37 
83.40 
86.41 
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Fig.No.15: STABILITY STUDY RELEASE DATA FOR FORMULATION (F7)            
AT 45oC/75% RH 
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Kinetics of drug release for optimized formulation F7 
     The optimized formulation F7 was introduced in to graphical treatment for kinetic of drug 
release. 
 
 
 
 IN VITRO DRUG RELEASE FORMULATION F7 
 
 
 
 
Fig.No.16: Zero order plot for formulation F7 
Regression=0.999 
 
 
 The optimized formulation F7 of nanoparticles is more suitable for parentral 
administration it shows good invitro release kinetic study. The zero order plots were obtained 
by plotting cumulative percentage drug release versus time. The regression value is 0.999. 
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 HIGUCHI ‘S PLOT: 
 
 
 
 
 
Fig.No.17: HIGUCHI’ S PLOT FOR FORMULATION F7 
Regression=0.843 
 
 Higuchi plot was made by plotting cumulative percentage % drug release against 
square root of time. The regression value was found to be 0.843.This indicates that diffusion 
is one of the mechanism of drug release. 
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 KORSEMEYER PLOT: 
 
                       
 
             Fig.No.18: KORSEMEYER’S PLOT FORMULATION F7 
 
 
 The graph was plotted between log cumulative % of drug release and log time. The n’ 
value was found to be 1.0126 indicated may nonfickian diffusion mediated. 
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Kinetic of drug release of first order for optimized formulation F7 
     The optimized formulation F7 was introduced into graphical treatment for kinetics of drug 
release. 
 
 
 
 
Fig.No.19: First order plot for formulation F7 
Regression = 0.7813 
 
The optimized formulation F7 of nanoparticles is more suitable for parentral 
administration it shows the invitro release kinetic study. The first order plots were obtained 
by plotting log remaining cumulative percentage drug release versus time. The regression 
value is 0.7813. 
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                                    7.  SUMMARY AND CONCLUSION 
 
The present study was aimed to develop a nanoparticulate drug delivery system of 
antihypertensive drug irbesartan using  polymer ( poly vinyl alcohol).The polymer enhances the 
binding of irbesartan  nanoparticles in specific or targeted site with sustained release of drug 
increasing therapeutic efficacy. These nanoparticles may also reduce the dose frequency with 
desired therapeutic response. 
 
All batches of nanoparticles (F1-F10) were prepared by nano precipitation method. 
 
The entrapment efficiency of the optimized formulation F7 (drug 50mg, polyvinyl 
alcohol 75mg, β –cyclodextin 10 mg) was 99.38 ±0.08 and invitro drug release was 98.46% after 
24 hours. It also obey the zero order, follows diffusion and erosion mechanism of release. 
 
Surface morphology of optimized formulation (F7) indicated that lrbesartan  
nanoparticles were found to be in average nanometer range(358.4nm) and showed ideal surface 
morphology. 
 
The stability test performed revealed that the formulation (F7) showed no change in its 
characters. The optimized formulation (F7) was also examined for zeta potential determinations. 
 
The formulation(F7) showed maximum deviation of 9.16 mV which demonstrated that 
the particles are separate and highly repelling property found to be more useful in decreasing 
opsonization and favors target specificity. 
 
The developed irbesartan nanoparticle formulation increases water solubility, reduces the 
dose frequency and improves the bioavailability of drug. 
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